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Abstract

DRUG AND VACCINE DEVELOPMENT FOR NEISSERIA GONORRHOEAEA

By Devin Cash, B.S.

A dissertation submitted in partial fulfillment of the requirements for the degree of Medical
Doctor-Doctor of Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2016

Major Director: Cynthia Nau Cornelissen, Ph.D.
Professor, Department of Microbiology and Immunology

Neisseria gonorrhoeae, the causative agent of the STI gonorrhea, is not preventable by
vaccination and is rapidly developing resistance to antibiotics. One important strategy for
gonococcal survival in the host is iron acquisition in the face of nutritional immunity. To
overcome iron limitation, the gonococcus expresses TonB dependent transporters (TdTs), outer
membrane proteins that facilitate nutrient acquisition. Of the TdTs, the transferrin (Tf),
lactoferrin (Lf), and hemoglobin (Hb) receptors hijack iron directly from host proteins, and
studies have already shown that the Tf receptor is essential for the initiation of human
infection. Given that the TdTs are virulence factors, they are widely conserved across strains,
and are not subject to antigenic variation, they are ideal targets for novel therapeutics and
xiv

vaccine development. As such, studies exploring these proteins and their potential as vaccine
candidates and antimicrobial targets are needed. In this study we report that loops of the Tf
receptor protein TbpA are not strongly immunogenic, and the antibodies raised against them
are incapable of inhibiting TbpA-Tf interactions on the gonococcal cell surface. We also report
that the loop 3 helix motif of TbpA is a critical functional domain for Tf-binding and iron uptake;
however, no single residue was identified that was essential for these functions. In addition, we
report the development of a platform for the structure-function analysis of HpuA, a member of
the poorly studied Hb receptor. We also present evidence that novel small molecules may be
able to inhibit TbpA-Tf interaction, presenting the Tf receptor as a novel, species-specific
antimicrobial target. Finally, we demonstrated that a novel drug, OSU-03012, has antimicrobial
activity against the gonococcus through down-regulation of DnaK, a protein chaperone. These
findings suggest that DnaK, a widely conserved protein, may be a universal target for
antimicrobial development. These studies provide insight into the structure function
relationship of TbpA, the drug potential of DnaK, and lay the framework for future
investigations of the TdTs for use in a multi-antigen vaccine.

xv

Chapter 1: Introduction

I. Neisseriaceae
The family Neisseriaceae, first proposed in 1933, included a group of Gram-negative,
oxidase- and catalase-positive, aerobic or facultatively anaerobic, non-spore-forming, rod- or
coccoid-shaped organisms and embraced four genera: Neisseria, Kingella, Acinetobacter and
Moraxella (1). Over time, this family has undergone several revisions, including the transfer of
genera Moraxella and Acinetobacter into the new family Moraxellaceae based on rRNA
analyses (2). Additionally, the genera Eikenella, Simonsiella (3), and Alysiella (4) were added to
the family Neisseriaceae, which comprises a major branch of the β-Proteobacteria.
Within the Neisseriaceae, the Neisseria species are non-motile, Gram-negative diplococci
with flattened sides that grow optimally at temperatures between 35-37°C (1). Within this
genus there are several species considered to be commensal in humans, and two species that
are pathogenic. Human associated Neisseria spp. can be identified by their patterns of acid
production from carbohydrates, their ability to reduce nitrate, and their ability to produce
polysaccharide from sucrose (5).

II. Pathogenic Neisseria species
Neisseria gonorrhoeae and Neisseria meningitidis are both considered human specific,
pathogenic Neisseria species; however, N. meningitidis can be carried asymptomatically. The
meningococcus frequently colonizes the nasopharynx of health individuals, and occasionally
goes on to cause disease, usually in small outbreaks. In contrast, the gonococcus is always
1

considered pathogenic, and most often infects the mucosal surfaces of the urogenital system,
the oronasopharynx, and the rectum. Most other Neisseria species are commensal, and can
colonize the oropharynx without causing disease (6). However, these species have been
associated with cases of endocarditis, meningitis, septicemia, otitis, bronchopneumonia, and
possibly genital tract disease (7). Due to these rare clinical presentations, these species are
considered opportunistic pathogens that only infect individuals with weakened immune
systems (5). Indeed, there is evidence that colonization with commensal Neisseria may be
protective against the pathogenic species (8).

III. Meningococcal Disease
A. Epidemiology
Neisseria meningitidis colonizes the nasopharynx in approximately 10% of people, where it
predominately exists as a member of the normal flora (9, 10). Among carriers, colonization lasts
months in 25% of individuals, is intermittent in about a third of colonized individuals, and the
remaining 40% are transiently colonized (11). Age is a large determinant of meningococcal
carriage. In North America and Europe, carriage rates are very low in the first years of life,
sharply increase in teenagers, peak in those aged between 20 and 24 years, and decline
afterwards (12). Meningococci are transmitted person to person by direct contact with nasal or
oral secretions or through inhalation of large droplet nuclei (13). Susceptibility to
meningococcal and carriage can be dramatically altered by environmental factors. Exposure to
tobacco smoke is correlated with meningococcal carriage and can increase risk of disease by
20% (14). In closed settings, such as residential schools or military barracks, transmission
2

increases dramatically and carriage rates may approach 100% (15, 16). Additionally, individuals
with defects in the terminal complement pathway or complement regulation are at greater risk
of recurrent and more serious meningococcal infections (17, 18).
Despite high rates of meningococcal carriage, disease incidence is rare with rates that vary
from 1 to 1000 cases per 100,000 individuals, depending on location (19). Indeed, it is thought
that nasopharyngeal colonization is an important immunizing process, which may protect
against future illness (13). Meningococcal infection may also be influenced by the season. In the
only area of the world with epidemic disease, the meningitis belt of Africa (defined as the area
between Ethiopia in the East to Senegal in the West), epidemics arise at the end of the dry
season (20, 21). N. meningitidis strains can be separated into 13 serogroups based on the
chemical structure of the polysaccharide capsule. Of the 13 serogroups, A, B, C, W135, X and Y
are responsible for greater than 90% of disease worldwide (19). Serogroup A causes the highest
incidence of disease, with pandemic outbreaks every 5-10 years since 1905 in the meningitis
belt of Africa. During these pandemics, infection rate can reach 1% of the population (22). The
bulk of infections in the Americas and Europe are caused by serogroup B, and to a lesser extent
serogroup C, with rates typically less than 10 per 100,000 population (22).
B. Disease
During colonization, meningococcal pilin and opacity proteins promote binding to epithelial
cells. The meningococcal adhesins stimulate epithelial cells to engulf meningococci into
phagocytic vacuoles, which may transverse the mucosal epithelium, granting the bacteria
access to subepithelial tissues (23). In a small percentage of individuals, N. meningitidis
penetrates the mucosa and gains access to the bloodstream, causing systemic disease (24).
3

Meningococcal bacteremia can result in the seeding of the meninges, pericardium and large
joints. Up to 50% of patients with meningococcal disease present with meningitis, with the
classic presentation of a sudden onset of headache, fever, and stiffness of the neck (25, 26). N.
meningitidis can be isolated from the bloodstream in up to 75% of patients with meningococcal
disease, but meningococcal sepsis, also called meningococcemia, occurs in only 5 to 20% of
patients (25). Meningococcemia is characterized by an abrupt onset of fever and a petechial or
purpuric rash, and is often associated with the rapid onset of hypotension, acute adrenal
hemorrhage, and multiorgan failure (26). Invasive meningococcal infection can also result in
pneumonia in 5 to 15% of patients; however, these infections are difficult to detect because
isolation of N. meningitidis from sputum does not differentiate between carriage and active
infection (26).
C. Treatment and Prevention
Until a century ago, meningococcal infection was fatal in up to 70% of infected individuals
(27). However, the development of several antimicrobial therapies has dramatically reduced
rates of mortality. Over the last two decades, mortality rates have remained stable at 9 to 12%
for all infections, but up to 40% for those with meningococcemia (26). Although mortality has
sharply declined, 11 to 19% of survivors of meningococcal disease will have serious sequelae,
including hearing loss, neurologic disability, or loss of a limb (28, 29).
Due to the serious nature of this infection, containment and prevention are key strategies
for combating illness. People in close contact with infected individuals are at elevated risk for
contracting the disease, and most secondary cases occur within 5 to 10 days of exposure to the
infected person (13). To limit spread of disease, rapid antimicrobial chemoprophylaxis is
4

implemented to close contacts of the patient. Optimal prophylaxis is achieved using systemic
antibiotics that effectively eliminate nasopharyngeal carriage of N. meningitidis, including
rifampin, ciprofloxacin, and ceftriaxone. Antimicrobial resistance is rare among N. meningitidis
isolates (30), but may be beginning to emerge (31).
Fortunately, great strides have been made in developing vaccines for meningococcal
infection. A polysaccharide vaccine against serogroups A, C, Y, and W-135 (MPSV4) has been
available since 1981, and has 85% clinical effectiveness in adults (32). Since it is a
polysaccharide only vaccine, it stimulates B-cells but not T-cells, and thus does not stimulate
immunologic memory or have any effect on meningococcal carriage (33). More recently,
protein conjugate vaccines have been developed that induce a T-cell dependent response,
which results in strong primary and anamestic responses (34). In the 2000s, quadravalent
conjugate meningococcal vaccines were introduced. Menactra (Sonofi Pasteur) and Menveo
(Novartis) are composed of serogroup A, C, Y, and W-135 capsular polysaccharides conjugated
to diphtheria toxoid and CRM197, respectively. GlaxoSmithKline released a trivalent vaccine,
Menhibrix, which contains N. meningitidis serogroup C and Y capsular polysaccharides, as well
as Haemophilus influenza type b capsular polysaccharide, conjugated to tetanus toxoid. While
these vaccines have been successful for the strains they cover, a vaccine was still needed for
serogroup B, which causes 50% of invasive meningococcal disease globally and 30% in the
United States (34).
Vaccine development for serogroup B was hindered due to the structure of the polysialic
acid in its capsule, which has a specific linkage structure found in many human tissues,
especially in the central nervous systems of fetuses and children (35). This molecular mimicry
5

was likely to reduce the immunogenicity of the capsule due to immunologic tolerance
developed in humans, and would have the potential to trigger an autoimmune disorder if
antibodies were generated to a self-antigen (36). Through the process of reverse vaccinology
(36) and subsequent testing, factor H binding protein (fHBP), Neisseria adhesion A (NadA), and
Neisseria heparin-binding antigen (NHBA) were identified as vaccine candidates (37). These
three proteins were combined with an outer membrane vesicle derived from a serogroup B
New Zealand strain (strain NZ98/254) to create the formulation for the 4CMenB vaccine
(Novartis), which was licensed in the United States in 2013. N. meningitidis strains are
considered sensitive to 4CMenB vaccine if they expresses the P1.4 subtype of PorA protein or if
1 of the 3 antigens has a sufficient level of expression (38). Studies have shown that if a strain
exceeds the positive threshold for only 1 of the 3 vaccine antigens, the probability of being
killed by the host antibodies is 80%, and the probability climbs to 96% if 2 out of 3 proteins
exceed the positive threshold (39). In 2014, another serogroup B meningococcal vaccine,
Trumemba (Pfizer), was licensed in the United States. This vaccine consists of two fHBP
variants, which are immunologically distinct (A05 and B01). Although these new vaccines have
generated promising results, continuing surveillance will be needed to determine immunity
duration and vaccine safety profiles.
D. Animal Models of Infection
Several animal models have been developed to characterize meningococcal infection.
Intraperitoneal models of infections have been developed in both mice and infant rats (40).
Although intraperitoneal inoculation isn’t the natural route of infection, these models are best
used to characterize virulence and protection profiles from immunization. The intraperitoneal
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mouse model is better for determining active resistance to infection, whereas the rat model
can only study passive resistance. However, the intraperitoneal mouse model requires
supplementation with exogenous iron sources, while the rat model does not. In contrast to the
intraperitoneal models, an intranasal mouse model of infection has been developed to assist
with characterizing mechanisms of meningococcal pathogenesis and disease progression (41).
Although these models allow for different aspects of meningococcal disease investigation,
they each have specific limitations, and are collectively limited by the fact that N. meninigitidis
is a human specific pathogen. Accordingly, several human host proteins are absent from these
models that may contribute to meningococcal pathogenesis. To address this concern,
humanized transgenic mice are being developed to more closely mimic human infection. Thus
far, mouse lines have separately been developed that express human CD46 (42), CEACAM1
(43), transferrin (44), and factor H protein (45). These newer models will allow for more
detailed investigation of specific components of menginococcal-host interactions that
contribute to infection.

IV. Gonococcal Disease
A. Epidemiology
Gonococcal infection is one of the oldest diseases known to man, dating back to at least
biblical times with references made in Leviticus 15: 1-3 (46). Neisseria gonorrhoeae, the
causative agent of the sexually-transmitted infection gonorrhea (47), is still a relevant medical
issue today as it is the second most commonly reported sexually transmitted infection (STI) in
the United States. Gonococcal disease affects approximately 106 million people worldwide
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according to WHO estimates (48), with >300,000 cases of gonorrhea reported each year in the
United States alone (49). A troubling contributor to these statistics is that infection with this
bacterium does not result in any protective immunity (50). The gonococcus is spread
predominately through sexual contact, which contributes to the correlation between age and
gonococcal infection. Adolescents and young adults (age 15 to 24) account for majority of new
cases every year. Additionally, ethnic minority groups, including African-Americans, Latinos, and
Native Americans, are disproportionately represented among those infected (51). Infection is
on the rise among populations of men who have sex with men (MSM), and it has been shown to
be more prevalent HIV positive individuals (52). The association between gonococcal and HIV
infections is well established (53, 54), and recent studies have demonstrated that gonococcal
infection increases HIV gene expression and viral replication (55). In other populations, women
often serve as reservoirs for the disease. Indeed, approximately 50% of women infected with
the gonococcus are asymptomatic, resulting in increased spread and more severe clinical
outcomes following infection (56). Although gonococcal infection is not as immediately serious
as meningococcal infection, the disease still creates a substantial financial burden on the health
system, with reports of spending approaching $1 billion per year in the US alone (57).
Individuals with gonococcal infection are frequently co-infected with Chlamydia trachomatis,
and therefore testing should always be performed for both infections (58).
B. Disease
The most well known form of gonococcal infection is gonorrhea, a disease of the genital
tract. N. gonorrhoeae invades mucosal and glandular surfaces of the genito-urinary system,
resulting in a local inflammatory response that involves recruitment of neutrophils and
8

macrophages. Typical infections in males initially cause urethritis, which can ascend to cause
prostatitis and epididymitis. Infections in men are symptomatic 90% of the time, and symptoms
typically begin 2 to 5 days after exposure (59). Infection in females begins with cervicitis and
urethritis, and then it ascends to cause pelvic inflammatory disease, salpingitis, and even
perihepatitis. In the minority of women that have symptoms, the incubation period is longer
than for men, at approximately 5 to 10 days after exposure (59). Although genital infections are
the most common, gonococcal disease can also manifest in other organ systems, including the
mouth, throat, eyes, and rectum. Because women are more likely to carry asymptomatic
infection, they are at greater risk for experiencing secondary complications compared to men
due to delay in treatment. Secondary complications for gonococcal infection include
disseminated gonococcal infection, septic arthritis, and ascension of the genital tract which
causes scarring that over time can cause ectopic pregnancy and infertility.
C. Treatment
The gonococcus has become increasingly drug resistant, with mounting evidence to suggest
that current pharmacotherapies may be soon rendered obsolete (60, 61). To date, the
characteristics of at least three multi-drug resistant isolates have been published, all of which
are fully resistant to ceftriaxone, the previously recommended single agent therapy for
treatment of gonorrhea (61-65). The World Health Organization and Centers for Disease
Control have recommended that the treatment options for N. gonorrhoeae should be easily
accessible, cost effective, and have more than a 95% cure rate as a single dose (66, 67). Due to
mounting antimicrobial resistance, the CDC updated the treatment guideline for the
management of gonococcal infections in 2015 (68). For all uncomplicated gonococcal infections
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of the cervix, urethra, pharynx, and rectum, the recommended therapy is a combination of one
dose of intramuscular ceftriaxone 250 mg plus one dose of oral azithromycin 1000 mg.
Coincidentally, this therapy would also cover Chlamydia infection, if present. Alternative drug
combinations, using single doses of azithromycin 2000 mg plus either oral gemifloxacin 320 mg
or intramuscular gentamicin 240 mg, have also been tested (69). Gonococcal eradication was
observed in 100% of the gentamicin/azithromycin group (202/202) and in 99.5% of
gemifloxacin/azithromycin group (198/199). No serious adverse events were reported;
however, gastrointestinal events were common in both groups, with over 25% of patients
experiencing nausea and approximately 20% experiencing diarrhea. Due to the success of this
trial, these drug combinations are now listed as alternative therapies for individuals with βlactam sensitivity (68). Although a few therapeutic options remain, increasing levels of
antimicrobial resistance, dwindling drug options, and lack of protective immunity post-infection
dictate the need for further drug and vaccine development research to prevent an era of
untreatable gonococcal infection.
D. Animal Models of Infection
The gonococcus is a human specific pathogen, and this host limitation has made animal
modeling of gonococcal infection difficult. At first, genital tract infection was only accomplished
in chimpanzees; however, their use is too costly to be a practical model for gonococcal infection
(70). Discoveries that the murine estrous cycle affected gonococcal colonization eventually
allowed for the development of a 17β-estradiol treated germ-free BALB/c mouse model of
infection that allowed for long-term colonization (71-73). Murine infection in this model
typically last from 12-14 days, but can last as long as 40 days depending on the method of
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estrogen administration (73). It is not precisely known how estrogen allows for gonococcal
colonization, but it hypothesized that it temporarily suppresses the mouse immune system
(73). This model succeeds in that the localization of infection closely mimics that of humans,
and like humans, mice do not develop a humoral memory response to gonococcal infection.
Although this model allows for some in vivo characterization of gonococcal infection, it also
has several limitations. During the course of infection, there are culture negative windows of
dramatically reduced recovery of bacteria, followed by returns to bacterial carriage (72).
Accordingly, multiple consecutive days of negative cultures are required to confirm that the
infection has cleared. In terms of genital tract physiology, vaginal pH in mice is substantially
higher than in humans (74), and mice do not undergo a period of menstrual bleeding (73). Both
of these factors may be relevant to the survival of the gonococcus in its niche, but are not able
to be tested with this model. Finally, as a host specific pathogen, there are many host-pathogen
interactions that are specific to human proteins that cannot be tested in this model, including
cell surface receptors, iron binding glycoproteins, and complement regulatory proteins. In order
to overcome these limitations, several lines of transgenic mice are needed. To date, several of
these transgenic mice have been developed, with mouse colonies that can express human
transferrin (44), human CEACAM1 (43), or human factor H protein (45). Although these single
transgene mice are helpful, the ultimate goal is to develop mice that can express multiple
human proteins to more closely model human infection.
V. N. gonorrhoeae virulence factors
N. gonorrhoeae possesses an array of surface-associated virulence factors that contribute to
interaction with host cells and development of infection (Fig. 1.1). These proteins contribute to
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Figure 1.1. Overview of gonococcal virulence factors.
Image of gonococcal cell with several surface-exposed virulence factors and brief descriptions
of their roles, adapted from (75).
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Figure 1.1. Overview of gonococcal virulence factors

Adapted from (75)
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adherence, invasion, and immune avoidance. In addition, many of these genes are subject to
one of two types of genetic variation: phase and antigenic. Phase variation can be considered a
reversible on/off switch mechanism for gene expression. Antigenic variation is the expression of
various alternative forms of an antigen on the cell surface. High frequency phase and antigenic
variation are major contributors to gonococcal immune avoidance.
A. Type IV Pilus
Like other gram-negative bacteria, N. gonorrhoeae produces a type IV pilus, which is a
filamentous polymer 6 nm in diameter and several micrometers in length that protrudes from
the cell surface (76). Systematic genetic analyses have identified 15 proteins (known as Pil
proteins) that are involved in the biogenesis, assembly and disassembly of pili (77). The pilus
fiber primarily consists of numerous subunits of the major pilin, PilE, arranged in a helical
configuration. In addition, several minor pilins, PilC, PilV, and PilX, can be incorporated in the
fiber to modulate its function (78). The crystal structure of gonococcal pilus was resolved in
1995 (79), and the structure has since been updated based on additional images generated
with cryo-electron microscopy (80).
The gonococcal pilus plays multiple roles in pathogenesis. It serves as a major adhesin to
eukaryotic cells (76), and also plays a role in self-agglutination (78). The pilus can also assemble
and disassemble rapidly, facilitated by the coordinate action of PilC and the ATPase PilT,
resulting in “twitching motility” (81, 82). Notably, the pilus is responsible for uptake of foreign
DNA from the extracellular milieu, thereby increasing the transformation frequency of bacteria
and maintaining the genetic diversity that is characteristic of Neisseria spp (83, 84).
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The pilus itself is subject to genetic variation, as it undergoes high frequency phase and
antigenic variation. Phase variation impacts the pilE gene, which contains a polyC-tract within
the structural gene. Changes in length of the polyC-tract can result in frameshift mutations,
which can turn the gene off by creation of a premature stop codon. Phase and antigenic
variation also occur from genetic recombination between the pilE expression locus and the one
of several distinct pil genes in the silent pilS locus (85, 86). This process is RecA dependent, nonreciprocal, and happens at high frequency during human infection (87). In addition to genetic
variation, the gonococcal pilus can undergo several distinct post-translational modifications,
including glycosylation, which can indirectly have an effect on cellular interactions (88).
B. Porin
Porins, the most abundant outer membrane proteins in Neisseria spp. (89), function as ion
and nutrient transport channels that are essential for neisserial viability (76, 90). N. meningitidis
encodes two porins: class 1 (PorA), which is phase variable (91), and either class 2 or class 3
(PorB). However, the PorA gene exists as a pseudogene in N. gonorrhoeae (92), and therefore
the gonococcus only expresses one porin, which is homologous to meningococcal PorB. PorB is
subclassified as either protein 1A (PorB1A) or protein 1B (PorB1B) (93).
In addition to their role in cell viability, these proteins also contribute to gonococcal
pathogenesis. Porins have been reported to translocate from the outer membrane of gonococci
into artificial membranes (94) as well as into that of the host cell membrane (95, 96).
Epidemiologic observations indicate a strong association of PorBIA with disseminated
gonococcal infections, whereas PorBIB-expressing strains have mostly been isolated from
patients with localized infections (97). This association has been supported by data
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demonstrating that PorB1A, but not PorB1B, expressing strains can invade epithelial cells, even
in the absence of opacity proteins (98). PorB1A has also been associated with serum resistance,
and mediates resistance to the alternative and classical complement pathways through
association with Factor H and C4b-binding protein, respectively (99-101). PorB1B is also capable
of binding C4b-binding protein, demonstrating that porins mediate serum resistance among
gonococcal isolates (99).
Porins also possess immunomodulatory properties. Translocation of PorB into the
membrane of activated neutrophils initiates a series of events that include a transient change in
the membrane potential (96), inhibition degranulation without affecting the NADPH oxidase
activity (102), and inhibition of actin polymerization and subsequent phagocytosis (103).
Further studies have shown that porin is also capable of arresting phagosome maturation
within macrophages, which may contribute to intracellular survival (104).
C. Lipooligosaccharide (LOS)
Lipopolysaccharide (LPS) is the major glycolipid expressed on the outer membrane of Gramnegative bacteria. LPS contains three structural regions: Lipid A, which anchors the LPS to the
bacterial membrane, a short oligosaccharide core, and a variable length repeating O-antigen
polysaccharide. In the pathogenic Neisseria, however, the LPS lacks O-antigen and is therefore
termed a lipooligosaccharide (LOS) (105). Although the LOS structure is stably expressed, there
are a variety of glycosyl transferases that modify the terminal sugars of the LOS (106). These
glycosyl transferases, encoded by lpt genes, are subject to phase variation due to polyG tracts
within their coding regions (107). Due to this phase variable expression, LOS undergoes high
frequency variation (10-2 per generation), resulting in substantial antigenic diversity.
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LOS, in addition to being an endotoxin, plays several roles in bacterial virulence. Gonococcal
LOS mimics the human glycosphingolipid paragloboside (108), and can bind to the human
asialoglyco-protein receptor (ASGP-R), which is present on human sperm (109). The LOS-ASGPR interactions also increases invasion of urethral epithelial cells (110). Some LOS variants can
also serve as acceptors for sialic acid deposition (111). The gonococcus is not able to synthesize
sialic acid, but it does encode a sialyltransferase (112, 113). During the course of infection, the
gonococcus can use host derived cytidine-5′-monophospho-N-acetylneuraminic acid (CMPNANA) as a sialyl donor (114, 115). The presence of sialic acid on gonococcal LOS confers serum
resistance (116), partially through binding of Factor H (117); however, it also impairs Opamediated invasion of some cell lines (118). This observation has led to the suggestion that LOS
antigenic phase variation may allow the gonococcus to fluctuate between invasive and serumresistant phenotypes, enhancing bacterial survival. Gonococcal LOS has also been implicated in
manipulation of host dendritic cells, directing the immune response to favor bacterial survival
(119). Although not directly linked to bacterial survival, it has also been discover that heptose
shedding from gonococcal LOS leads to increased HIV viral replication, which has substantial
public health implications (55).
D. Opacity (Opa) proteins
Opacity (opa) proteins are a family of related transmembrane proteins that form eightstranded β-barrel structures in the outer membrane of the bacterium with four surfaceexposed loops (76). Gonococcal strains typically have up to 11 opa loci, whereas meningococcal
strains typically have 4 to 5 opa loci (120). Opas were originally named for their ability to impart
an opaque phenotype in gonococcal colonies (121). More recently, these proteins are
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considered a family of invasions that mediate invasion of epithelial cells and leukocytes (122125). The importance of these proteins for infection is demonstrated by their expression in
both natural and experimental infections (121, 126, 127).
Like the other proteins listed here, Opas are subject to phase and antigenic variation. All
opa genes contain tandem repeats [CTCTT]n that cause high-frequency phase variable
expression (128, 129). As a result, the gonococcus can reversibly express none, one, or multiple
Opa proteins at the same time, although no strain has been isolated with more the 4 Opas
expressed (130). In addition, horizontal gene transfer promotes the formation of hybrid
recombinant opa loci (131).
Opa proteins can be categorized based on their receptor tropisms. Opas have been
demonstrated to bind to two set of host receptors: heparin sulfate proteoglycans (132, 133)
and extracellular matrix proteins vitronectin and fibronectin (134, 135), and the
carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family of receptors (136,
137). In addition to being invasins, Opas can possess immune-modulatory capabilities.
Interactions between gonococcal Opa proteins and CEACAM1 on B cells result in cell death,
which lowers antibody production (138). Among T cells, CEACAM1 interaction with gonococcal
Opas arrests activation of T cells and prevents proliferation (139). Further studies have shown
that Opas are involved in directing the host immune response away from Th1/Th2 responses,
and towards the more favorable Th-17 response through both TGF-β (140, 141) and IL-10
dependent mechanisms (140, 141).
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VI. Iron sources in humans
Iron is an essential nutrient for microorganisms, and acquisition of iron is recognized as one
of the key steps in the survival of a pathogen within its host (142). Iron, a transition metal,
exists in two readily inter-convertible redox states: ferrous, Fe2+ or ferric, Fe3+. Iron’s properties
make it an extremely versatile prosthetic component for incorporation into proteins as a
biocatalyst or electron carrier, and it is involved in many major biological processes including
respiration and DNA biosynthesis (143). Although iron has many beneficial attributes, it also
possesses significant potential for toxicity. In the presence of radical oxygen species, which are
natural products of aerobic metabolism (144), iron can cause the creation highly damaging
hydroxyl radicals through the Fenton reaction [Fe2+ + H2O2 → Fe3+ OH- + HO·] (145).
Though the human body has significant amounts of iron, its availability is tightly regulated
to prevent against toxicity. Indeed, iron is distinct from other important nutrients because it is
not a freely available in the host. In aerobic environments, iron exists primarily in the oxidized,
ferric form, which at pH 7, has a solubility of 1.4×10−9 M (146). Iron withholding, known as
nutritional immunity, is a mechanism of innate defense against invading microorganisms (147).
During microbial invasion, humans can suppress the amount of iron circulating on carrier
proteins in the blood and also decrease dietary absorption of iron to further minimize its
presence (148). Therefore, the ability of microorganisms to acquire iron in a hostile host
environment is considered a virulence determinant. In the absence of free iron, microbes can
often hijack host proteins to meet their iron demands. Several human iron sources are
described below.
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A. Transferrin
Transferrin (Tf) is an 80 KDa glycoprotein found in the blood that transports iron throughout
the body. It has a bi-lobed structure (N and C lobes), with each lobe containing a high affinity
binding site for a single Fe3+ atom (149). The N- and C-lobes are ~40% identical and likely arose
from gene duplication followed by fusion (150). Each lobe folds into two subdomains, and the
Fe3+ binds in a deep cleft formed between the two subdomains. In human serum, where Tf
concentrations are ~25 to 50 μM, approximately 30% of Tf is iron bound (151, 152). Of the
monoferric Tf, the iron is not evenly distributed; there is a slight bias towards N-lobe iron
binding (153). At pH 7.4, the human transferrin receptor (TFR1), which is present on all iron
requiring cells (152), binds Tf with nanomolar affinities (Kd ~4 to 26 nM depending on iron
bound state) (154). Once the ligand is bound, the TFR1/Tf complex undergoes clathrindependent endocytosis (155, 156). The endosome is acidified to ~pH 5.6 and the combination
of low pH and salt induce iron release from Tf. Critically, apo-Tf still has high affinity for TFR1 at
endosomal pH so it remains bound. This allows the complex to be recycled to the cell surface
instead of being degraded, and the apo-Tf is released back into the serum (152).
B. Lactoferrin
Lactoferrin (Lf) is an 80 KDa glycoprotein of the transferrin family. Lf is found in mucosal
secretions, including tears, saliva, vaginal fluids, semen, nasal and bronchial secretions, bile,
gastrointestinal fluids, urine, and colostrums (157). LF is the second most abundant protein in
milk (158), after caseins, and it can also be found in blood plasma and amniotic fluid. Although
Lf is present at low levels in serum (3.8–8.8 nM), it is a significant component of mucosal
secretions (6–13 μM) (159). Similar to Tf, Lf has a bilobed structure where the lobes are 37%
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identical, and each lobe possess a high affinity Fe3+ binding site (160). Unlike Tf, Lf can retain
iron binding over a wide pH range, including extremely acidic pH (161). Lf also serves a role in
innate immunity. Lf is a significant component of secondary neutrophil granules (155, 162), and
at sites of inflammation, Lf concentration can rise to 200 μg/mL (163, 163, 163). Lf has
antimicrobial activity attributed to two distinct mechanisms. The first is its iron scavenging
ability which deprives microorganisms of this nutrient. The second is that the N terminus of Lf
can undergo proteolysis to produce antimicrobial compounds known as lactoferricins (164166). These positively charged molecules interact with negatively charged bacterial surface
components, including LPS and lipoteichoic acid, and cause membrane destabilization,
increasing the effects from other innate effectors like lysozyme, which ultimately results in cell
death (157, 167).
C. Ferritin
When intracellular iron exceeds cellular requirements, the redox potential of the excess is
controlled by sequestration of iron in ferritin. Mammalian ferritins are heteropolymers of 24
subunits of two types, designated H for heavy, and L for light, where both types of chains are
required for normal function of ferritin. The mature protein shell has a molecular weight near
450 kDa, with subunits arranged to form a nearly spherical structure enclosing a cavity capable
of accommodating up to 4500 oxygen- and hydroxyl-bridged iron atoms (168). During
inflammation and infection, serum iron decreases and cell associated iron increases, leading to
increases in the amount of ferritin in macrophages, and greater amounts of iron stored per
ferritin molecule (169, 170). Hemosiderin, a water-insoluble degradation product of ferritin, can
result from incomplete lysosomal processing (171). The iron core of hemosiderins is more
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heterogeneous than ferritin, and slower to release iron (172); however, iron release from
hemosiderin does occur under acidic conditions (173).
D. Heme/Hemoproteins
Approximately 70% of the iron in the human body is contained within heme, a porphyrin
ring that coordinates one ferrous iron atom (174). Heme solubilizes iron and enhances its
catalytic activity by at least 5 orders of magnitude (175). Due to this high catalytic activity,
heme is critical for functions involved in oxygenation reactions, oxidative stress responses,
electron transport, oxygen transport, oxygen sensing, and oxygen storage (176). Although heme
is an essential biomolecule, excess free heme is toxic to cells due to its lipophilic nature, lipid
peroxidation capacity, and ability to catalyze the production of reactive oxygen species (176).
Accordingly, over 95% of heme is bound to proteins (hemoproteins), 67% of which is bound to
hemoglobin within erythrocytes. Hemoglobin is a tetramer composed of two α- and two βsubunits, each of which binds a heme molecule. Although the majority of heme is intracellular,
hemolysis results in extracellular hemoglobin in the blood at concentrations of 80 to 800 nM
(159). Upon hemolysis, Hb disintegrates into αβ dimers, which are rapidly bound by excess
serum haptoglobin (177). Haptoglobin stabilizes and protects against the toxic effects of Hb,
and chaperones Hb until its clearance through receptor mediated endocytosis in monocytes
(178). Damaged hemoproteins can also result in free heme in the blood, which is bound by
hemopexin, and to a lesser degree albumin. Similar to haptoglobin, hemopexin protects against
the toxic effects of heme, and shuttles it to the liver for clearance (177).
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E. Siderophores
Siderophores are secreted, low molecular mass (1 kDa) iron chelating compounds used by
many microorganisms to overcome the iron limitations of the human host (142). Siderophores
are divided into three categories based on the structure of their iron ligation groups:
catecholate, hydroxamate, and hydroxycarboxylate (179). The binding power of the
siderophore for iron, for which values of the dissociation constant (Kd) range from 1022 to 1050
(142), is sufficiently strong for the siderophore to remove iron attached to ferritin, Tf, and Lf,
but not to remove iron from hemoproteins (142). Once secreted, siderophores chelate free or
protein-bound iron in the environment. After acquiring iron, the siderophore can be imported
whole, and the iron harvested, by any bacterium that possesses the siderophore specific
receptor (180). Many species of bacteria can utilize xenosiderophores, which are siderophores
that a bacterium does not produce, but for which it does have the receptor (181).
In response to the use of siderophores by bacteria to steal iron from host iron-sequestering
proteins, humans produce proteins that sequester ferric siderophore complexes away from
bacterial siderophore receptors (182). These proteins belong to the lipocalin family of binding
proteins, and are termed siderocalins for siderophore-binding lipocalins. Scn, the best studied
of these proteins, possess a highly polyspecific recognition mechanism to sequester a wide
range of enterobactin-like siderophores and the chemically distinct carboxymycobactins (183).
The importance of these proteins is demonstrated in Scn knock-out mice, which are
significantly more susceptible to infections with siderophore dependent bacteria (184). In a
step further in the evolutionary battle for iron access, some bacteria have evolved mechanisms
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to glycosylate their siderophores, making them no longer susceptible to siderocalin binding
(185).
Similar to siderophores, proteins called hemophores have been discovered that can directly
bind heme or acquire heme from hemoproteins (186). These proteins are structurally diverse
and can be surface-associated or secreted (187). Hemophores can deliver heme to cells that
express the hemophore specific receptor; however, unlike siderophores, only the heme is
internalized (187).

VII. Iron acquisition systems of N. gonorrhoeae
As the gonococcus has evolved to be a human-specific pathogen, it has developed an array
of iron acquisition systems to survive within its host. Unlike many enteric bacteria, the
gonococcus does not secrete siderophores (188). Instead, it possesses several surface receptors
designed to hijack iron directly from host iron and heme transporting proteins.
A. Two component systems
The gonococcus encodes three distinct two-component systems for iron acquisition, the
best studied of which is the transferrin receptor (Fig. 1.1). The transferrin receptor is composed
of an integral, outer-membrane, TonB dependent transporter (TdT), TbpA, and a surface
exposed lipoprotein, TbpB. The structure of TbpA is similar to other TonB dependent
transporters: a transmembrane β-barrel comprised of 22 amphipathic β-strands, surface
exposed loops, and a folded plug domain inside the barrel (189, 190). TbpB has a bilobed
structure, with homologous N and C lobes that both contribute to N-lobe transferrin binding
(191, 192). Both TbpA and TbpB have nM affinities for Tf; however, only TbpA is required for Tf24

iron internalization (193-195). Although TbpB is not essential for uptake of Tf-iron, it does
increase the efficiency of Tf iron acquisition due to its preferential recruitment of iron laden Tf
(196). The transferrin receptor is not subject to phase or antigenic variation. The tbpA and tbpB
genes are encoded by an iron repressed operon, and have been found in all sequenced
gonococcal strains (197). The importance of the Tf receptor for gonococcal pathogenesis has
been demonstrated in human infection trials, in which the absence of the Tf receptor resulted
in attenuated virulence (198).
The lactoferrin receptor is analogous to the Tf receptor, where there is a TdT, LbpA, and a
surface exposed lipoprotein, LbpB (199, 200). Like the tbpAB operon, the lbpAB genes are
encoded on an iron repressed operon where the lipoprotein is encoded before the TdT (201).
Unlike the Tf receptor, the Lf receptor is subject to phase variation due to a polyC-tract in the
coding region of lbpB (199). While the Lf receptor is present in all meningococcal strains, it is
absent in approximately 50% of gonococcal isolates due to a large deletion encompassing parts
of lbpB and lbpA (201). The Lbps are not required for human infection (198), but can serve as a
means of acquiring iron in the absence of the Tf receptor (201).
The hemoglobin receptor is the last of the two component iron acquisition systems
encoded by the gonococcus. The Hb receptor is also comprised of a TdT, HpuB, and a
lipoprotein, HpuA. Although the naming convention is reversed, in all three cases the
lipoprotein is encoded before the TdT in an iron repressed operon (202). The Hb receptor, like
the Lf receptor, is phase variable due to a polynucleotide repeat in the lipoprotein gene, hpuA
(203). The hemoglobin receptor differs from the other two component systems in three distinct
ways. Unlike the Tf and Lf receptors, the Hpus extract heme instead of atomic iron (204). The
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Hb receptor can obtain heme from hemoglobin alone, or hemoglobin complexed to
haptoglobin (202, 205). The heme acquired through this receptor is sufficient as a sole iron
source to support gonococcal growth (206). This receptor is also unique in that it may not be
specific to human hemoglobin, as binding has been demonstrated to an array of other species’
hemoglobin (207). Lastly, the Hb receptor differs from the other two component systems in
that both proteins are required for heme internalization (206).
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Figure 1.2. Overview of two-component iron acquisition systems.
Schematic representation of the gonococcal two-component iron acquisition systems,
representing the transferrin, lactoferrin, and hemoglobin receptors. The TonB-dependent
transporter (TdT) is shown as a barrel traversing the outer-membrane (OM), with several
surface exposed loops and a plug domain occluding the barrel. The companion lipoprotein is
shown on the outer leaflet of the OM. The TonB/ExbB/ExbD system is shown embedded in the
inner membrane (IM) and extending into the periplasm. TonB interacts with the plug of the TdT
to facilitate iron transport. Iron that reaches the periplasm is bound by the periplasmic binding
protein FbpA, which shuttles the iron to the inner membrane permease FbpB. Upon hydrolysis
of ATP by the ATPase FbpC, iron is transported through FbpB into the cytoplasm.
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Figure 1.2. Overview of two-component iron acquisition systems
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B. Single component systems
In addition to the two component iron acquisition systems, Neisseria species also encode
single component systems in which a TdT is an independent receptor. The HmbR Hb receptor in
N. meningitidis is a single component receptor, and is subject to phase variation (208, 209).
However, HmbR is not expressed by the gonococcus due to a premature stop codon in the
coding sequence (210). FetA, a receptor for catechol-type siderophores, is another single
component receptor (211). Like many other surface proteins, FetA is subject to phase variation
due to a polynucleotide repeat in the gene promoter (212). Lastly, there is some evidence that
TdfF, a TonB dependent protein of unknown function, may also be a single component iron
transporter (213). TdfF is specific to the pathogenic Neisseria, and can only been detected in
iron deplete conditions in the presence of serum (197, 214). A tdfF mutant was demonstrated
to be defective for intracellular survival, and this defect could be reversed with addition of iron.
These data suggest that TdfF may participate in intracellular iron acquisition, which would
enhance survival; however, the ligand has not yet been identified.
C. TonB dependent transport
All of the previously described transporters are TonB dependent, meaning that subsequent
to the ligand binding to its receptor, the transmembrane transport of the iron or iron chelate is
dependent on the Ton system for metabolic energy (215, 216). The Ton system is composed of
TonB, ExbB, and ExbD, and their respective genes are encoded in an iron repressed operon
(217, 218). TonB has 3 functional domains: an N-terminal transmembrane domain, a prolinerich spacer located in the periplasm, and a C terminal domain that interacts with TonBdependent receptors (219). Although the mechanism by which TonB transduces energy has not
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been fully defined, it has been demonstrated that the energy that drives the Ton system is
harnessed from the proton motive force (220). Once energized, TonB interacts with the TonB
Box, a conserved region within the plug domain of TdTs, and facilitates transfer of the substrate
across the membrane and into the periplasm (Fig. 1.1).
D. Cytoplasmic transport
Once the iron or iron chelate arrives in the periplasm, the previously described iron uptake
pathways utilize a periplasmic binding protein (PBP) and an inner membrane ATP-binding
cassette (ABC) transporter to deliver the substrate to the cytoplasm (221). The periplasmic
transfer of ferric iron derived from Tf and Lf requires FbpA, a PBP that in its apo form has been
hypothesized to dock to the periplasmic surface of TbpA (222). Once ferrated, holo-FbpA
traverses the periplasm and associates with the cytoplasmic permease protein, FbpB. FbpB in
cooperation with FbpC and ATP hydrolysis, facilitates iron transport across the cytoplasmic
membrane (223). An analogous ABC transport system is hypothesized to exist for heme
transport, but to date it has not been identified. Siderophore utilization through FetA requires
the PBP FetB, and the putative FetCDEF ABC transporter (211). Both transport systems, FbpABC
and FetBCDEF, are iron repressed (212, 217).
E. Regulation
All of the TdTs involved in iron acquisition are subject to iron-dependent repression, which
is mediated by the ferric uptake regulator (Fur) protein. In high iron conditions, Fur complexes
with ferrous iron, dimerizes, and binds to a DNA sequence called a “Fur box,” which generally
overlaps with the promoter region of iron-repressed genes (218, 224). Fur binding inhibits RNA
production through the inaccessibility of the promoter to the RNA polymerase or the inability of
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the RNA polymerase to transcribe the entire gene (213). When iron is a limiting nutrient, apoFur dissociates from the Fur box, alleviating repression and allowing gene transcription. There
are no known direct activators of iron uptake proteins in Neisseria species; however, Furrepressed, AraC-like regulator MpeR activates expression of fetA (225).

VIII. Vaccine Efforts
Gonococcal infection does not elicit protective immunity, and with mounting drug
resistance, the development of a preventative vaccine is urgently needed. Unfortunately, many
of the gonococcal surface proteins and polysaccharides are subject to high-frequency variation
(as described above), limiting their potential as vaccine candidates. The gonococcus is also
capable of blocking antibody deposition on its surface. Decoration of LOS with sialic acid has
been demonstrated to prevent antibody deposition on gonococcal porin (226). Similarly,
antibodies developed against a conserved protein, RmpM, can also prevent porin antibody
deposition (227). These distinct mechanisms of antibody blocking present difficulties even if an
appropriate vaccine antigen is found. Another general barrier to successful vaccine
development is that the genital tract is devoid of specialized lymphatic tissue, and naturally
needs to be tolerant of foreign antigens (228, 229). Fortunately, progress has been made in
generating genital tract immune responses through intranasal immunization (230-232).
In addition to these general limitations, there are additional antigen specific concerns for
vaccine candidacy. Compounding gonococcal pilin variation, it has been demonstrated that the
conserved pilin domains are immunosilent, virtually eliminating the capacity for crossprotective pilin based immunity (233). Although Opa proteins are selected for during human
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infection, evidence shows that Opa proteins alone (139) or in outer-membrane vesicle (234)
can suppress host T cell activity. These findings suggest that any gonococcal vaccine would need
to omit Opa proteins in order to optimize the host immune response. Despite the protections
afforded to porin described above, specific, cross-reactive, bactericidal antibodies have been
elicited against PorB in the serum and mucosal secretions (235). However, these studies relied
on outer-membrane vesicles preparations that contained LOS, which is toxic.
In order to expand the scope of antigens for vaccine development, the TdTs have been
considered as immunogens (236). It is thought that using vaccines to target iron receptors could
work through a two pronged approach: limiting access to an essential nutrient and also
complement and cell mediated killing. Of the TdTs, the Tf receptor stands out as an ideal
candidate, based on its consistent expression and requirement for initiation of infection (198).
Preliminary work in a mouse model of infection began by conjugating TbpA and TbpB to the B
subunit of cholera toxin, which resulted in antibodies in the serum and vaginal secretions. It
was also determined that although TbpB was more immunogenic, TbpA antibodies elicited
better cross protection among strains (232). In a second attempt to use the Tbps as
immunogens, a chimeras composed of peptide fragments of TbpA loop 2 combined the N lobe
of TbpB were conjugated to the A2 subunit of cholera toxin. These immunizations yielded
bactericidal and cross protective antibodies, and the vaginal secretions from immunized mice
were capable of interfering with in vitro gonococcal Tf-dependent growth (237). These results
suggest that TdTs are credible vaccine targets, and warrant further studies.
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IX. Research Objectives
The goal of the research described in this thesis is to characterize the structure-function
relationships of select gonococcal TdTs, and to investigate novel approaches to gonococcal
antimicrobial development. Within this framework, four main objectives were pursued. First,
TbpA surface exposed loops were evaluated as immunogens, and the TbpA loop 3 helix was
probed for its role in Tf-iron acquisition. Second, a platform was developed to characterize the
structure-function relationship of the Hb receptor protein HpuA. Third, novel small molecules
were developed and tested for inhibition of TbpA function. Lastly, an investigational cancer
drug, OSU-01032, was tested for antimicrobial properties in gonococcal culture. These studies
have more fully described the function and vaccine capacity of TbpA, while also finding
preliminary data that it could serve as a novel drug target. Additionally, these studies describe
DnaK, a prokaryotic protein folding chaperone, as a novel target for antimicrobial therapy.
These studies provide additional insight into the TdTs and other drug targets, which may
advance the development of novel protective and/or therapeutic strategies against the
gonococcus.
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Chapter 2: Materials and Methods

I. Bacterial strains and maintenance
Strains and plasmids used in these studies are listed in Tables 1 and 2. Plasmids were
propagated in either Top10 (Invitrogen), XL-10 Gold (Agilent Technologies), or Stellar (Clontech)
E. coli cells. The expression strains for pUNCH412 and pVCU757 were BL21(DE3) (New England
Biolabs) and C41(DE3) (Lucigen), respectively. E. coli was cultured in Luria-Bertani broth in the
presence of 34 μg/ml chloramphenicol (Sigma), 200 μg/ml ampicillin (Sigma), or 50 μg/ml
kanamycin (Sigma). Gonococcal cells were propagated on GC medium base (GCB; Difco) agar
with Kellogg’s Supplement 1 (238) and 12 μM Fe(NO3)3 at 37°C with 5% atmospheric CO2. When
necessary, chloramphenicol was added to GCB agar plates at a concentration of 1 μg/ml for
selection of the resistance phenotype. Growth conditions for specific assays are listed below.

II. Bacterial iron deplete growth conditions
For growth under iron-stressed conditions on solid media, gonococci were either grown
overnight on GCB agar plates with the addition of 5 μM Desferal (Sigma), or on chemically
define medium (CDM) (239) agar plates. For transferrin-iron dependent solid phase growth,
CDM agar plates were supplemented with 2.5 μM 10% iron-saturated human Tf (Sigma). To
achieve iron stress in liquid media, gonococcal strains were cultured from GCB agar plates into
liquid CDM, which had been pretreated with Chelex-100 (Bio-Rad). Typical liquid culture growth
in CDM involved starting a culture at approximately 20 Klett units (KU) and growing until
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approximately 40 KU, at which point the cultures were diluted back to 15 KU and allowed to
grow for 4 additional hours.

III. Gonococcal mutant construction
Mutants made in this study were made with a combination of traditional digestion and
ligation cloning, Quikchange cloning (Agilent), and In-fusion cloning (Clontech). For specific
cloning strategies, see individual chapters. Primers used in this study are listed in Table 3. After
mutant construction, plasmids were linearized in preparation for gonococcal transformation.
Piliated gonococci were grown on GCB agar plates. Cells were then transferred to GC medium
plus Kellogg’s supplement 1 and 10mM MgCl2. Bacteria were incubated with linearized plasmid
DNA in liquid suspension, and then plated on GCB agar plates containing appropriate
antibiotics, either 1 μg/ml chloramphenicol or 50 μg/ml kanamycin.

IV. Solid phase ligand-blocking assay
Solid phase ligand blocking assays were performed as previously described (194, 240, 241).
Briefly, gonococcal strains were iron-stressed in liquid CDM for 4 hours and E. coli strains were
grown in LB broth with 1 mM IPTG to induce TbpA expression. Bacteria were standardized to
culture density and applied to a nitrocellulose membrane (GE Health Life Sciences). Blots were
blocked with 5% skim milk (BioRad) in low-salt Tris-buffered saline (LS-TBS) (50 mM Tris, 150
mM NaCl [pH 7.5]) for 1 hour, washed 5 times with LS-TBS, and subsequently incubated with
HRP-Tf (Jackson ImmunoResearch) at 200 ng/mL plus either TbpA loop-specific mouse antisera
(190), polyclonal TbpA rabbit antisera (242), unlabeled human Tf (hTf) (Sigma), or unlabeled
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bovine Tf (bTf) (Sigma) for 1 hour. Blots were washed 5 more times with LS-TBS, then they were
developed with the Opti-4CN (Bio-Rad) development system.

V. Whole cell ligand blocking ELISA
Maxisorp microtiter dishes (Nunc) were coated with 0.01% poly-L-lysine (Sigma) in PBS
overnight at 4°C. Gonococci were iron-stressed by overnight growth on GCB agar plates
containing 5 μM Desferal. Gonococcal cells were harvested from the agar plates and
standardized to an OD600 of 1.0 in phosphate buffered saline (PBS). One hundred microliters of
the cell suspension was applied in triplicate for each strain and allowed to incubate on the plate
for 1 hour. The microtiter plate was washed 5 times with PBS, and then 200 μl of 3% bovine
serum albumin (BSA; Pierce) in PBS was added for 1 hour. After blocker was removed, antipeptide or anti-holo TbpA serum was diluted 1:50 in 3% BSA, applied to the cells for 1 hour, and
then washed 5 times with PBS. Then, 1 μg/ml HRP-Tf in 3% BSA was applied for 1 hour,
followed by 5 washes with PBS. Subsequently, 100 μl of 1-Step Slow-TMB (Thermo) was added
to colorimetrically detect the amount of HRP-Tf bound to cells in each well. After 10 minutes,
100 μl of 2 M sulfuric acid was added to each well to stop the reaction. The microtiter plate was
then read at OD420. Antibody blocking specificity was determined by performing these assays on
bacterial strains without transferrin receptor proteins (gonococcal strain FA6815 and E. coli
expressing empty vector) and subtracting these values from the experimental strains prior to
normalization to the positive control.
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VI. Transferrin binding assay
Assays were performed in a manner similar to that described above for the whole cell ELISA
except that the step in which anti-peptide and anti-holo TbpA antisera were added was
omitted. HRP-Tf was used at concentrations ranging from 2 nM to 50 nM. A standard curve of
HRP-Tf, diluted in PBS, was prepared with concentrations ranging from 10 ng/mL to 1 μg/mL.
Cell-containing wells were compared to the standard curve to determine the amount of Tf
bound. Data was then normalized to the positive control.

VII. Radiolabeled iron uptake assay
Tf-iron uptake assays were performed as described previously (192, 196, 243, 244). Briefly,
apo-human Tf (Sigma) was saturated to 20% with
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Fe (Perkin-Elmer). Gonococci were iron-

stressed in liquid CDM for 3 hours, and then 100 l of the culture was applied in triplicate to
two multiscreen microtiter dishes (Millipore). Each microtiter well contained 1.5% BSA as a
non-specific protein blocker. One dish received 215 μM potassium cyanide (KCN) to determine
counts bound but not internalized. Both plates were incubated for 10 minutes at 37°C and 5%
CO2. Subsequently, 3 μM 20% 55Fe-saturated human Tf was added to each well, and plates were
again incubated for 30 minutes to allow iron internalization. Following incubation, each plate
was filtered, washed with citrate buffer (100 mM NaCitrate, 1 mM MgCl2, 0.25 mM CaCl2 [pH
7.0]), dried, and individual filters from each well were removed. Radioactive iron was detected
using a Beckman LS6500 beta counter. All counts were averaged, and surface associated counts
(KCN condition) were subtracted from total counts to determine the specific amount of iron
internalized in 30 minutes. Internalized iron was standardized to micrograms of total cellular
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protein in 100 μl of culture, as determined by bicinchoninic acid assay (BCA; Pierce). Final data
is presented as values normalized to the positive control.

VIII. Protein analysis methods
A. Whole cell lysates preparation
To analyze iron repressed proteins, gonococcal strains were grown in liquid CDM as
described above. After growth, cultures were standardized, and centrifuged at 16,000 x g for 2
minutes. Then, supernatants were removed, the pellet was re-suspended in 100 μL of Laemmli
solubilizing buffer (245), and the samples were frozen at -20° C until use. Immediately prior to
SDS-PAGE, lysates were supplemented with 5% β-mercaptoethanol, passed through a 28 gauge
syringe several times to reduce viscosity, and boiled for 3 minutes.
B. SDS-PAGE
Lysate proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) on 7.5% Tris-HCl Criterion precast gels (BioRad) using a Criterion vertical
electrophoresis cell (BioRad).
C. Western blotting
Proteins separated by SDS-PAGE were transferred to nitrocellulose membranes submerged
in 16 mM Tris base, 120 mM glycine, and 20% methanol (246) in a Criterion blotter (BioRad) at
28 mAmps for 16 hours. Membranes were stained with Ponceau S solution (0.1% w/v Ponceau
S, 5% acetic acid) to confirm equal protein loading in each lane prior to immunodetection, and
then de-stained with in distilled water. For detection of TbpA, proteins were blocked with 5%
BSA in high-salt TBS (20 mM Tris, 500 mM NaCl [pH 7.5], 0.02% NaN3, 0.05% Tween 20).
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Blocked membranes were probed with polyclonal rabbit serum against full-length TbpA (194).
Goat anti-rabbit IgG conjugated to alkaline phosphatase (AP; BioRad) was used as the
secondary antibody. AP conjugates were detected using the nitroblue tetrazolium (NBT) and 5bromo-4-chloro-3-indolylphosphate (BCIP) development system (Sigma).

IX. Protease accessibility assay
Protease accessibility experiments were performed as described previously (193). Briefly,
whole iron-stressed gonococci were exposed to trypsin for 0, 10, 20, or 30 minutes, the trypsin
was quenched with aprotonin (Sigma), then cultures were pelleted, lysed, and subjected to
SDS-PAGE and western blotting.

X. OSU and PDE-5 inhibitor growth assays
OSU-03012 (OSU) and the PDE-5 inhibitors sildenafil (Sil), tadalafil (Tad), and vardenafil
(Var) were dissolved in 100% dimethyl sulfoxide (DMSO) to concentrations up to 4000 fold
higher than the desired final concentration due to the toxic effects of DMSO on N. gonorrhoeae
growth. The drug was then diluted to twofold the desired final concentration in CDM, and 100
μL was applied in triplicate to an untreated 96-well flat-bottom microtiter dish (Corning).
Gonococcal strains were grown in liquid CDM until doubling as described above. Instead of
diluting the culture to 15 KU, cultures were diluted to OD600 0.2 with fresh CDM, and 100 μL
standardized culture was applied to the drug-loaded microtiter dish in triplicate. The initial
OD600 of each well was measured using a Vmax kinetic plate reader (Molecular Devices), and
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then the microtiter plates were placed on a platform shaker at 200 rpm inside a standing
incubator at 37 °C with 5% CO2. The OD600 was measured hourly until assay termination.

XI. Small molecule inhibitor assays
These assays were carried out similarly to the whole cell ligand blocking ELISAs described
above with one exception. The inhibitory molecules are applied before the blocking step, due to
possible inhibition of the albumin, at 50 mM concentration dissolved in PBS. For this assay, the
negative control is unlabeled transferrin, which acts as a competitive inhibitor of HRP-Tf. The
positive control is a vehicle only condition, which is most often DMSO. Final data is presented
as values normalized to the positive control.

XII. Statistics
Comparison of results between the positive control and mutant strains was performed after
analysis of variance using the Student’s t test. Pairwise comparisons with a P-value of <0.05
were considered statistically significant. ELISAs and radiolabeled iron uptake assays shown are
the means of multiple individual concentration points from studies performed at least in
triplicate (± SEM).

*Some methods adapted from: Copyright © American Society for Microbiology, Infection
and Immunity, 83, 2015, 4438-4449, doi:10.1128/IAI.00762-15
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Table 1. Bacterial strains used in this study

Strain

Description

Ref. or
Source

E. coli
BL21(DE3)

fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS

New England

λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 Biolabs
∆nin5
C41(DE3)

F−ompT hsdSB(rB−mB−)(rB−mB−)gal dcm (DE3)

Lucigen

uncharacterized derivative of BL21 (DE3)
Top10

F− mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1

Invitrogen

deoR araD139 Δ(ara-leu)7697 galU galK rpsL(Strr) endA1
nupG
Stellar

F–, endA1, supE44, thi-1, recA1, relA1, gyrA96, phoA, Φ80d

Clontech

lacZΔ M15, Δ (lacZYA-argF) U169, Δ (mrr-hsdRMS-mcrBC),
ΔmcrA, λ–
XL-10 Gold

endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183

Agilent

Δ(mcrCB-hsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15

Technologies

Tn10(TetR Amy CmR)]
N. gonorrhoeae
FA19

Wild type

(247)
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FA6747

TbpA- (tbpA::mTn3cat)

(194)

FA6905

TbpB- (ΔtbpB)

(193)

FA6815

TbpAB- (tbpB::Ω)

(196)

FA1090

Wild type (ΔlbpA, HpuAB off)

(249)

H041

Multi-drug resistant isolate

(61)

F89

Multi-drug resistant isolate

(63)

MCV511

L3HA(343) TbpA Lbp− (tbpA∇HA lbpB::Ω)

(250)

MCV512

L3HA(343) TbpA TbpB− Lbp− (tbpA∇HA lbpB::Ω ΔtbpB)

(250)

MCV161

TbpA K351A point mutation TbpB- (ΔtbpB)

(242)

MCV162

TbpA D355A point mutation TbpB- (ΔtbpB)

(242)

MCV163

TbpA D355K point mutation TbpB- (ΔtbpB)

(242)

MCV164

TbpA N357A point mutation TbpB- (ΔtbpB)

(242)

MCV165

TbpA Q358A point mutation TbpB- (ΔtbpB)

(242)

MCV166

TbpA K359A point mutation TbpB- (ΔtbpB)

(242)

MCV167

TbpA K359E point mutation TbpB- (ΔtbpB)

(242)

MCV168

TbpA K359R point mutation TbpB- (ΔtbpB)

(242)

MCV169

TbpA Q360A point mutation TbpB- (ΔtbpB)

(242)

MCV170

TbpA Q360E point mutation TbpB- (ΔtbpB)

(242)

MCV171

TbpA Q360K point mutation TbpB- (ΔtbpB)

(242)

MCV172

TbpA Loop 3 Helix Deletion (T350-A361) TbpB- (ΔtbpB)

(242)

MCV181

TbpA K351A point mutation

(242)

MCV182

TbpA D355A point mutation

(242)
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MCV183

TbpA D355K point mutation

(242)

MCV184

TbpA N357A point mutation

(242)

MCV185

TbpA Q358A point mutation

(242)

MCV186

TbpA K359A point mutation

(242)

MCV187

TbpA K359E point mutation

(242)

MCV188

TbpA K359R point mutation

(242)

MCV189

TbpA Q360A point mutation

(242)

MCV190

TbpA Q360E point mutation

(242)

MCV191

TbpA Q360K point mutation

(242)

MCV192

TbpA Loop 3 Helix Deletion (T350-A361)

(242)

MCV140

HpuA- (hpuA::aphA-3)

This study
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Table 2. Plasmids used in this study
Plasmid

Description

Ref. or Source

pHSS6-GCU

Vector containing gonococcal uptake sequence (Kanr)

(248)

pUNCH412

FA19 tbpA in pET-11

(251)

pUNCH755

Vector containing truncated and nonfunctional tbpB gene, full

(196)

length tbpA gene, and tbpA downstream region with an
mTn3Cm insertion
pKH37

Neisseria lctP-aspC complementation construct

(252)

pUC18K

pUC-18 with aphA-3 kanamycin resistance gene

(253)

pVCU150

pHSS6-GCU containing tbpA gene with K351A mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU151

pHSS6-GCU containing tbpA gene with D355A mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU152

pHSS6-GCU containing tbpA gene with D355K mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU153

pHSS6-GCU containing tbpA gene with N357A mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU154

pHSS6-GCU containing tbpA gene with Q358A mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU155

pHSS6-GCU containing tbpA gene with K359A mutation, novel
silent BamHI site at tbpA bp 1488-1493, and no stop codon
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(242)

pVCU156

pHSS6-GCU containing tbpA gene with K359E mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU157

pHSS6-GCU containing tbpA gene with K359R mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU158

pHSS6-GCU containing tbpA gene with Q360A mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU159

pHSS6-GCU containing tbpA gene with Q360E mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU160

pHSS6-GCU containing tbpA gene with Q360K mutation, novel

(242)

silent BamHI site at tbpA bp 1488-1493, and no stop codon
pVCU161

pUNCH755 containing tbpA gene from pVCU150

(242)

pVCU162

pUNCH755 containing tbpA gene from pVCU151

(242)

pVCU163

pUNCH755 containing tbpA gene from pVCU152

(242)

pVCU164

pUNCH755 containing tbpA gene from pVCU153

(242)

pVCU165

pUNCH755 containing tbpA gene from pVCU154

(242)

pVCU166

pUNCH755 containing tbpA gene from pVCU155

(242)

pVCU167

pUNCH755 containing tbpA gene from pVCU156

(242)

pVCU168

pUNCH755 containing tbpA gene from pVCU157

(242)

pVCU169

pUNCH755 containing tbpA gene from pVCU158

(242)

pVCU170

pUNCH755 containing tbpA gene from pVCU159

(242)

pVCU171

pUNCH755 containing tbpA gene from pVCU160

(242)
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pVCU172

pUNCH755 containing tbpA gene with deletion from bp 1453-

(242)

1488 (loop 3 helix region)
pVCU173

hpuA wt in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU174

hpuA Y78A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU175

hpuA F79A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU176

hpuA Y81A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU177

hpuA Y111A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU178

hpuA D115A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU179

hpuA F116A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU180

hpuA S140R in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU181

hpuA G141R in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU182

hpuA Y226A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU183

hpuA Y227A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU184

hpuA F295A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU185

hpuA R299A in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU186

hpuA CC136/137SS in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU187

hpuA Δ77-82 in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU188

hpuA Δ111-116 in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU189

hpuA Δ225-31 in pCVD005, locked phase-on

Dr. Stephen Hare

pVCU234

pKH37 with RBS added between PacI and SmaI

This study

pVCU235

pVCU234 with hpuA from pVCU173 at SmaI site

This study

pVCU236

pVCU234 with hpuA from pVCU174 between SmaI and XhoI

This study
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pVCU237

pVCU234 with hpuA from pVCU175 between SmaI and XhoI

This study

pVCU238

pVCU234 with hpuA from pVCU176 between SmaI and XhoI

This study

pVCU247

pVCU234 with hpuA from pVCU185 between SmaI and XhoI

This study

pVCU249

pVCU234 with hpuA from pVCU187 between SmaI and XhoI

This study

pVCU250

pVCU234 with hpuA from pVCU188 between SmaI and XhoI

This study

pVCU251

pVCU234 with hpuA from pVCU189 between SmaI and XhoI

This study

pVCU252

pVCU403 with hpuA R299A inserted at the SmaI site

This study

pVCU253

pVCU252 with aphA-3 KnR cassette in PpuMI site

This study

pVCU403

pUC18 with the gonococcal uptake sequence

pVCU757

FA1090 tbpA in pET22b

(254)
This study

47

Table 3. Primers used in this study
Primer

Use

Sequence (5’-3’)

oVCU745

Fwd: tbpA loop 3 sequencing

CGGTCGTGGCTGTTCCGCCC

oVCU747

Fwd: tbpA loop 3 amplification

CGGGGGAAATCCGCGCCC

oVCU748

Rev: tbpA loop 3 amplification

CCGATGCCCTGCCGGTCGTAAGAG

oVCU750

Fwd: tbpB deletion screening

TCGGGCGATGAAGGCGAAACAACTTCCA

oVCU752

Rev: tbpB deletion screening

CTGCATAAGCGGGCAGCGCAGTCAT

oVCU785

S: tbpA loop 3 helix deletion

GTTCCGGCATTTCTGGGATCCTTGCGCGGC

oVCU786

AS: tbpA loop 3 helix deletion

GCCGCGCAAGGATCCCAGAAATGCCGGAAC

oVCU790

Fwd: tbpA ApaI-RsrII sequencing

GCAAAAACGGGGGTCACGAAAAGTGTAAAGCG

oVCU791

Fwd: tbpA ApaI-RsrII sequencing

GCACACCAAAAGCCGCTACGGTTTGGAATATGTC

oVCU814

S: RBS inserted into pKH37

TAAAAGGAGCCC

oVCU815

AS: RBS inserted into pKH37

GGGCTCCTTTTAAT

oVCU816

Fwd: pKH37 sequencing

CTAGGCACCCCAGGCTTTACAC

oVCU817

Fwd: hpuA sequencing

TCGCCGACGGCAGCCGCATCTTTA

oVCU818

Fwd: hpuA amplification

CAAAGCCCTGCCCTTACTGCCGCTT

oVCU819

Rev: hpuA amplification

GGGAGCGGTCGCCGTCAAAGG

oVCU821

Fwd: In-fusion hpuA into

AATTAAAAGGAGCCCAATTCATG-

pVCU234 SmaI site

AAATACAAAGCCCTGCCCTTACTG
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oVCU822

Rev: In-fusion hpuA into

GAATTCCTGCAGCCCTTATTGTTT-

pVCU234 SmaI site
oVCU823

Fwd: In-fusion hpuA into

AGTAAGGTGGTTGGTATCTTGACTGGTG
CTCTAGAGGATCCCCATGAAATA-

pVCU403 SmaI site
oVCU824

Rev: In-fusion hpuA into

CAAAGCCCTGCCCTTACTGCCG
TCGAGCTCGGTACCCTTATTGTTTAGTAA-

pVCU403 SmaI site
oVCU825

Fwd: In-fusion aphA-3 into

GGTGGTTGGTATCTTGACTGGTGTCATC
GGGCGTGGATAGGTCCCCGGGT-

pVCU252 PpuMI site
oVCU826

Rev: In-fusion aphA-3 into

GACTAACTAGGAGGAATAAATGG
TTTCGCCGTTGGGACCCCGGGTC-

pVCU252 PpuMI site
oVCU841

Rev: hpuA slipstrand sequencing

ATTATTCCCTCCAGGT
TCTGCTGCGGCTCGGCGCGTC

Fwd, Forward; Rev, Reverse; S, Sense; AS, anti-sense
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Chapter 3: The Function and Vaccine Potential of Gonococcal TbpA Extracellular Loops

I. Introduction
One approach to development of therapeutics has been to target how the gonococcus
acquires iron, an essential nutrient for nearly all microorganisms (255). During human infection,
microorganisms are confronted with the challenge of obtaining iron in an environment that has
evolved to specifically restrict its availability. In humans, iron is circulated throughout the body
bound to several transport proteins, including lactoferrin and transferrin (Tf). These iron
binding proteins minimize free iron concentrations, which helps to reduce free radical
generation as well as to starve any invading microbes. In response to this iron-limitation, many
bacteria produce siderophores to compete with these human proteins for iron (256). However,
N. gonorrhoeae has evolved the ability to acquire iron directly from these human proteins.
The gonococcus expresses receptors that can extract iron or heme from Tf, lactoferrin and
hemoglobin, but the receptors are not universally expressed (213, 236). The lactoferrin
receptor proteins, LbpA and LbpB, are only expressed in approximately 50% of strains (215,
247). The hemoglobin receptor proteins, HpuA and HpuB, are expressed only in isolates from
women in the first half of the menstrual cycle due to phase variation (257). By contrast, the Tf
receptor system composed of an integral, outer-membrane, TonB dependent transporter,
TbpA, and a surface exposed lipoprotein, TbpB, is expressed in 100% of clinical isolates (258).
This set of human adapted receptors has made the gonococcus well suited to surviving in the
iron-limited environment of the human host.
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Iron acquisition systems are potential targets for novel drug therapies as well as for vaccine
development. Because the gonococcal Tf receptors are not subject to phase or antigenic
variation, are present in all clinical isolates, and are necessary for initiation of infection in
humans (198), they stand out as ideal candidates for further investigation. Much work has
already been done to probe this receptor complex for structure-function relationships and
vaccine potential (213, 236, 258). Recently, the Tf receptors, TbpA and TbpB, were crystallized
from the closely-related pathogen Neisseria meningitidis, which share 94% and 69% identity
with the respective proteins in N. gonorrhoeae strain FA19 (190, 191). The structural studies
provided the molecular details for how these receptors interact with Tf and will significantly
contribute to the study of these proteins for therapeutic development. Based on the structure
of TbpA, experiments were performed to test various surface exposed epitopes as immunogens
and to determine if antibodies raised against these regions could interrupt protein function
(190). The results of these studies were promising; however, they were performed using
recombinant N. meningitidis TbpA in an in vitro assay. Here, we follow up these studies to test
the degree to which these antibodies inhibit ligand binding to TbpA in the native bacterium N.
gonorrhoeae. Further, we developed our own loop specific antibodies in an attempt to improve
their inhibitory efficiency. To probe the structure-function relationships of this receptor, we
built on previous work to target the TbpA loop 3 helix, a motif located in close proximity to the
iron-chelation center within the C-lobe cleft of Tf (Fig. 3.1). Based on the TbpA crystal structure
and previous evidence that interruption of loop 3 led to a loss of protein function (250), this
motif is predicted to be a key to protein function. To assess the contribution of the loop 3 helix
to protein function, site specific mutagenesis of polar helix residues and a total helix deletion
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were employed, followed by ligand binding and radiolabeled iron uptake assays. Mutants
created were also tested for the ability to grow on Tf as a sole iron source.
The studies described here demonstrate that the original loop antibodies had only modest
abilities to block ligand binding to TbpA. Similarly, newly-generated loop-specific antibodies led
to modest inhibition of ligand binding to TbpA. However, unlike the original antibodies, the
newer antibodies had a greater effect on the gonococcus than in recombinant E. coli. With
regards to the loop 3 helix, reduction of TbpA function could be achieved with single amino acid
mutations; however, the co-receptor, TbpB, could largely compensate for these defects in TbpA
function. All singly mutated strains were capable of growth on poorly saturated Tf; however, a
total helix deletion strain could not grow under these conditions. This work provides new
insights into improved antibody development against TbpA loop peptides, which will enhance
vaccine efforts going forward. The current study also demonstrates that the entire loop 3 helix
significantly contributes to TbpA function, but that there is no single amino acid that is crucial.
This information contributes to our expanding understanding of key ligand-interacting domains,
which will likely be needed in order to optimize immunogen interaction with the host immune
system during vaccination (259)
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Figure 3.1. Homology model for TbpA from gonococcal strain FA19.
A) A sequence alignment of TbpA from N. meningitidis strain K454 (NmTbpA) and from N.
gonorrhoeae strain FA19 (NgTbpA), which are 94% identical in sequence. This alignment served
as the basis for homology modeling of TbpA from strain FA19. B) Based on the complex crystal
structure with NmTbpA, human Tf (hTf-C/hTf-N) (shown in gold) was modeled interacting with
NgTbpA (shown in light green), with the plug domain shown in red and the loop 3 (L3) helix
shown in dark green. The C1 and C2 domain of the C-lobe of hTf, which directly interact with
TbpA are also indicated. C) Loops 3, 7, 11 and part of the plug were selected for initial antibody
blocking studies against TbpA from strain K454. Highlighted in magenta are the conserved
regions of the NgTbpA model, to which those antibodies were developed. Pairwise comparisons
of the peptide sequences are also shown.
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Figure 3.1. Homology model for TbpA from gonococcal strain FA19
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II. Results
A. Antibodies raised against linear TbpA loop peptides minimally inhibit ligand
binding to gonococcal whole cells
Recent studies (190) reported the TbpA crystal structure from N. meningitidis and identified
surface exposed loops that facilitated substantial interaction with human Tf (Fig. 3.1). Linear
peptide domains from several interactive loops were used as antigens in mice, and the
subsequently produced sera were applied to E. coli strains expressing recombinant
meningococcal TbpA. In recombinant E. coli, these antibodies were individually capable of
blocking human Tf binding by approximately 50%; however the previous study did not address
whether the antibodies were capable of direct interaction with TbpA in whole Neisseria cells
(190). To investigate this in N. gonorrhoeae, we first used the structure of TbpA from N.
meningitidis strain K454 to create a homology model of TbpA (Fig. 3.1). Because the selected
loops have highly conserved sequences (Fig. 3.1A), we tested whether the antibodies generated
against the meningococcal antigens could block ligand binding in the gonococcus. We
implemented a solid-phase binding assay using whole iron-stressed gonococci to address this
question. We first demonstrated the specificity of this assay by showing that unlabeled hTF, but
not bovine Tf (bTf), was capable of blocking deposition of horseradish peroxidase (HRP) tagged
Tf (Fig. 3.2A). We then determined that the loop antibodies alone and in combination were
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Figure 3.2. Solid phase antibody-mediated ligand blocking assays.
Whole iron-stressed gonococci or E. coli expressing recombinant TbpA were applied to a
nitrocellulose membrane and allowed to dry. A) Blots were blocked with either 20 μg/mL hTf or
bovine Tf (negative control), followed by the application of HRP-Tf. After washing, HRP was
detected using Opti4CN (BioRad). Positive control contains no blocking agent (-) and therefore
represents maximal hTf binding. B) Blots were blocked with antibodies, followed by the
application of HRP-Tf. Peroxidase activity was detected using Opti4CN. Also tested was an
antibody raised against full-length TbpA (anti-TbpA). Negative controls are strains in which
TbpA is absent (A-/B-). C) A similar assay was performed using whole cells in a microtiter dish
for an ELISA (n=3). TMB (Thermo) was used as the peroxidase substrate, and absorbance was
measured at OD420. The positive control is the condition without antibody (No Ab), and the
negative control is incubation with unlabeled Tf. Data represents specific binding by subtracting
values obtained from strains without transferrin receptors from the experimental strains.
Significant differences are noted, where * represents P<.01, and # represents P<.05. Statistics
were calculated using the Student’s t test.
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Figure 3.2. Solid phase antibody-mediated ligand blocking assays
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unable to substantially block ligand binding (Fig. 3.2B). An antibody developed against fulllength TbpA was capable of modest blocking. These conclusions were further supported by
antibody mediated ligand blocking ELISAs (Fig. 3.2C). When quantified, none of the antibodies
was capable of accomplishing greater than 20% inhibition of ligand binding on the gonococcal
surface. Interestingly, the antibodies had a larger inhibitory effect on the E. coli strain overexpressing TbpA. This phenomenon is more pronounced when evaluating the effects of the
holo-TbpA antibody, which only inhibited 13% of ligand binding in the gonococcus, but resulted
in an 85% reduction in ligand binding in E. coli. With the evidence that these loop antibodies
were insufficient to significantly abrogate ligand binding, TbpA loop antibodies were
regenerated using a different approach in an effort to optimize their inhibitory characteristics.
B. Antibodies raised against cyclized TbpA loop peptides demonstrate modest Tf
blocking on whole cells
In reviewing the way the original TbpA loop antibodies were designed, several areas for
possible improvement were discovered. The first was that the linear epitopes may not have
taken on the appropriate 3D conformation required to target surface exposed, folded TbpA.
The second was that the antibodies were developed against peptides with N. meningitidis
sequence, which is not identical to the gonococcal sequence (Fig. 3.1), particularly in loop 7.
Lastly, the peptide fragments were short, often less than half the length of the entire surface
exposed loop. In the redesign of the loop antibodies, all three of these concerns were
addressed. The peptides were designed to contain gonococcal sequence, were substantially
extended in length, and were cyclized by adding cysteine residues to both ends (Table 4). Mice
were immunized subcutaneously using Titermax as the adjuvant, with boosters given at days 21
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Table 4. Peptide sequences for second generation immunizations

Loop

Peptide Sequence

Loop 3

CTKAVFDANQKQAGSLRGNGKYAGNHKC

Loop 7

CRLPSFAEMYGWRSGDKIKAVKIDPC

Loop 11

CRYVTWENVRQTAAGAVNQHKNVGVYNRYAAPGRC
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and 42. On first attempt, titers for loop 7 and loop 11 derived antibodies were robust, but loop
3 was found to be poorly immunogenic. After analyzing the peptide sequence for MHC class II
epitopes, the loop 3 peptide had a weak score compared to the other loop peptides. A second
attempt at loop 3 peptide immunization was performed, adding ovalbumin to the peptide and
Titermax adjuvant, which resulted in improved titers. With the new sera (second generation),
the solid phase ligand blocking assay described above was repeated. Despite the additional
considerations applied to their design, there was no detectable ligand blocking capacity for the
second generation antibodies (Fig. 3.3A). Again, these results were supported by antibody
mediated ligand blocking ELISAs (Fig. 3.3B). The second generation antibodies had comparable
effects to the original antibodies (Fig. 3.2C) on the gonococcal surface, with reductions in ligand
binding of 11- 17%. However, the redesigned antibodies had less inhibitory effect on the
recombinant TbpA over-expressing E. coli strain. Although no greater inhibitory effect was
obtained with the redesigned antibodies, these data suggest that there are differences in the
presentation of TbpA between E. coli and the gonococcus. This is most prominently shown with
our holo-TbpA control antibody, which demonstrated substantial Tf blocking in E. coli, but very
little blocking in the gonococcus. Accordingly, differences in bacterial surfaces should be taken
into consideration in future studies. Having addressed the interaction of loop-specific
antibodies with the native bacterium, focus was shifted to probing the structure-function
properties of the loop 3 helix of TbpA, which was hypothesized to be a key functional domain.

60

Figure 3.3. Antibody-mediated ligand blocking assays for second generation loop-specific
antibodies.
Whole, iron-stressed gonococci or E. coli expressing recombinant TbpA were applied to a
nitrocellulose membrane and allowed to dry. A) To determine loop-antibody blocking
capability, blots were blocked with antibodies, followed by the application of HRP-Tf. For both
blots, HRP was detected using Opti4CN. The condition labeled (–) contained no antibody and
therefore represents the maximal amount of hTf bound. B) A similar assay was performed using
whole cells in a microtiter dish for an ELISA (n=3). TMB (Thermo) was used as the peroxidase
substrate, and absorbance was measured at OD420. The positive control is the condition without
antibody (No Ab), and the negative control is incubation with unlabeled hTf (Tf). Data
represents specific binding by subtracting values obtained from strains without transferrin
receptors from the experimental strains. Significant differences are noted, where * represents
P<.01, and # represents P<.05. Statistics were calculated using the Student’s t test.
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Figure 3.3. Antibody-mediated ligand blocking assays for second generation loop-specific
antibodies
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C. Creation of TbpA loop 3 mutants
Within the iron chelation center in Tf, a triad of pH sensing residues has been shown
previously to control iron binding affinity (258, 260). The crystal structure of TbpA suggests that
a polar residue on the loop 3 helix might be able to destabilize the triad’s charge balance in Tf,
leading to iron release. To test this hypothesis, substitution mutations for all of the polar
residues on the loop 3 helix were created (Fig. 3.4, Table 3). Site-directed point mutations and
deletions were constructed using the Quikchange system (Agilent). Briefly, the tbpA gene was
amplified from strain FA19 and inserted into pHSS6-GCU (248) at the EcoRI restriction site.
Subsequently, a silent BamHI restriction site was added adjacent to the DNA encoding the loop
3 helix. Mutagenic primers were used for creating point mutants resulting in new plasmids with
point mutations in tbpA. The resulting plasmids (pVCU150-160) were then digested with ApaI
and RsrII to obtain an approximately 870 bp region of tbpA containing the mutations. The
pUNCH755 plasmid (Fig. 3.5), which contains a truncated tbpB gene, the full tbpA gene, and the
tbpA downstream region containing a chloramphenicol resistance gene, was equivalently
digested. The wild-type ApaI-RsrII tbpA region of pUNCH755 was replaced by the mutated ApaIRsrII regions from plasmids pVCU150-160, resulting in plasmids pVCU161-171. Top10 E. coli
cells were then transformed with the newly constructed plasmids, with selection for
chloramphenicol resistance as described. Because the new plasmids with mutated tbpA also
contained a truncated tbpB gene, a single gonococcal transformation yielded colonies that had
mutated TbpA with or without functional TbpB, depending on the distance between crossovers
(Fig. 3.5). Transformants were analyzed for the presence or absence of the complete tbpB gene
by PCR. PCR amplification of tbpA was followed by restriction with BamHI to confirm that the
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mutagenized region was incorporated into the chromosome. The tbpA PCR products were also
sequenced to confirm that the desired mutations were successfully incorporated into the
gonococcal chromosome.
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Figure 3.4. TbpA loop 3 helix polar residues.
Loop 3 helix with all polar residues displayed as stick models. All residues displayed were
mutagenized for this study as listed in Table 3.
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Figure 3.4. TbpA loop 3 helix polar residues
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Table 5. Mutagenesis of TbpA Loop 3 helix residues

Pos.

Wild Type

Mutations

351

Lysine

Alanine

355

Asp Acid

Alanine, Lysine

357

Asparagine

Alanine

358

Glutamine

Alanine

359

Lysine

Alanine, Glutamic Acid, Arginine

360

Glutamine

Alanine, Glutamic Acid, Lysine
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Figure 3.5. Gonococcal transformation with pUNCH755 derived plasmids pVCU161-171.
Image demonstrating how transformation with a single plasmid construct can result in two
distinct genotypes following allelic exchange. The downstream crossover location is constrained
by selection with chloramphenicol, whereas the upstream crossover can occur anywhere in
tbpA or the truncated tbpB. If the crossover occurs upstream of the tbpB deletion, as seen on
the left, the result is a TbpB- phenotype. Conversely, if the crossover occurs downstream of the
deletion location, as shown on the right, the result is a TbpB+ phenotype.
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Figure 3.5. Gonococcal transformation with pUNCH755 derived plasmids pVCU161-171
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D. Loop 3 helix mutant TbpA proteins are impaired for Tf binding and iron uptake in
the absence of TbpB
For all newly created mutants, TbpA expression was determined to be equal to wild-type by
western blot (Fig. 3.6). As the first metric of protein function, we assessed the ability of
mutagenized TbpA to bind to its ligand, hTf. In order to detect a binding defect specific for
TbpA, whole cell ELISAs with TbpB deficient strains were implemented. In these assays there
were two negative controls. The “Comp” condition (Fig. 3.7), or competitive inhibition,
contained excess unlabeled hTf applied with HRP-labeled Tf. The 6905 L3HA condition contains
a tbpB deletion strain that simultaneously has an HA epitope insertion in TbpA loop 3. This
strain has been previously shown to be incapable of binding hTf (250). In the current study, we
determined that the singly substituted TbpA proteins were able to bind Tf between 40 and 80%
of wild-type levels, while the loop 3 helix deletion (L3HΔ) mutant bound Tf at approximately 9%
wild-type levels (Fig. 3.7). Next, the ability of each mutated TbpA to mediate iron internalization
was quantified using a radiolabeled iron uptake assay. This assay employs the same 6905 L3HA
strain as a negative control. In these experiments we determined that the singly substituted
TbpA proteins were able to internalize iron between 14 and 47% of wild-type levels, while the
loop 3 helix deletion mutant internalized iron at less than 1% of wild-type levels (Fig. 3.8). These
data demonstrate that all of the single residue mutations substantially impacted TbpA function.
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Figure 3.6. TbpA expression determination by western blot.
WT and mutant gonococci were iron stressed in liquid CDM for 4 hours, standardized to cell
density, pelleted, and lysed. Lysates were subjected to a bicinchoninic acid assay (Thermo) to
assess protein levels, and then evenly loaded for SDS-PAGE and subsequent transfer to
nitrocellulose. Equivalent protein loading was confirmed by ponceau staining. The western blot
was probed with polyclonal TbpA antibody, and developed with the NBT/BCIP development
system (Sigma). TbpA bands are present at 100 kDa.
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Figure 3.6. TbpA expression determination by western blot
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Figure 3.7. TbpA-Tf binding ELISAs in TbpB- strains.
Whole, iron-stressed, TbpB deficient gonococcal cells were applied to microtiter dishes for
ELISAs using HRP-labeled Tf as the ligand. FA6905 (WT) serves as the positive control, and
FA6905 L3HA (L3HA) and excess competitor hTf condition (Comp) serve as negative controls. All
data was normalized to FA6905. Data shown represents the means +/- standard errors for at
least three independent binding experiments. For all mutants when compared to the positive
control, P<.001, with the exception of Q360K, where P<.01. Statistics were calculated using the
Student’s t test.
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Figure 3.7. TbpA-Tf binding ELISAs in TbpB- strains
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Figure 3.8. Iron internalization by TbpB deficient strains.
Whole, iron-stressed, TbpB deficient gonococcal cells were applied to microtiter dishes for
radiolabeled iron uptake assays. Iron uptake was calculated as counts/μg protein. Specific
uptake was calculated by subtracting +KCN counts from those count generated from
metabolically active cells. Specifically internalized iron counts were then normalized to that
from FA6905 (WT TbpA). FA6905 serves as the positive control, and FA6905 L3HA (L3HA) and
excess competitor hTf condition (Comp) serve as negative controls. Data shown represents the
means +/- standard errors for at least three independent binding experiments. For all mutants
when compared to the positive control, P<.001. Statistics were calculated using the Student’s t
test.
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Figure 3.8. Iron internalization by TbpB deficient strains
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E. TbpB expression enables iron internalization in the loop 3 helix mutant TbpA
proteins
We next assessed whether TbpB was able to restore iron uptake function in strains with a
defective- TbpA transport protein, as this phenomenon has been observed in our previous
studies (250). This hypothesis was tested with a subset of the isogenic TbpA mutants, coexpressing a functional TbpB, in the radiolabeled iron uptake assay described above. In the
presence of TbpB, all point mutants demonstrated greatly increased iron uptake, to levels 7098% of WT (Fig. 3.9). The helix deletion strain, however, continued to demonstrate a severe
defect, with iron uptake rates below 5% of wild-type. The range of defects seen in the Tfbinding ELISA and the iron uptake assays were quite varied for single residue substitutions, but
no information about the ability to survive on Tf as a sole iron source can be derived from these
experiments. We therefore set out to determine if any of the TbpA mutants, in the presence or
absence of TbpB, were capable of growing on iron depleted media supplemented with partially
ferrated Tf.
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Figure 3.9. Iron internalization by TbpB expressing strains.
Whole, iron-stressed, gonococcal cells were applied to microtiter dishes for radiolabeled iron
uptake assays. Iron uptake was calculated as counts/μg protein. The amount of iron
internalized was determined by subtracting +KCN counts from the counts generated with
metabolically active cells. Internalized counts were then normalized to that from FA19 (WT
TbpA). FA19 (WT) serves as the positive control, and FA6905 L3HA (L3HA, B-) and FA19 L3HA
(L3HA, B+) serve as negative controls. Data shown represents the means +/- standard errors for
at least three independent binding experiments. Significant differences are noted, where *
represents P<.001, and # represents P<.01. Statistics were calculated using the Student’s t test.
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Figure 3.9. Iron internalization by TbpB expressing strains
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F. Strains with TbpA loop 3 helix mutations are capable of growth on Tf as a sole iron
source
In order to assess the abilities of the TbpA mutants to grow on Tf as a sole iron source, we
grew all 12 tbpA mutants, with and without a functional TbpB, on GCB agar plates. The next
day, single colonies were patched onto CDM agar plates containing 10% ferrated Tf, and grown
for 48 hours at 37°C with 5% CO2. Since Tf in circulation in the human body is 30% ferrated, this
condition represents a saturation level below that which is physiologically achieved. At 48
hours, all strains except the negative control and the helix deletion strains were capable of
growth on Tf as a sole iron source (Fig. 3.10).
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Figure 3.10. Growth of tbpA mutants on hTf as a sole iron source.
A) CDM + 10% saturated hTf agar plates with 6 strains grown per plate. Each plate has FA6905
as a positive control and FA6747 as a negative control in addition to several mutants with point
mutations. B) Plate layout diagram describing the phenotypes of the strains streaked on each
sector of the above plates.
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Figure 3.10. Growth of tbpA mutants on hTf as a sole iron source
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G. TbpA in the loop 3 helix mutants is surface exposed
To confirm the surface exposure of the mutated TbpA proteins, we used a proteolytic
cleavage assay on whole iron-stressed gonococci. Cells were subjected to a time course of
trypsin digestion and then processed for preparation of whole cell lysates. Whole cell proteins
were separated by SDS-PAGE and then transferred to nitrocellulose for Western blotting. The
presence of TbpB did not affect the digest pattern (Fig. 3.11), and all single residue mutants had
the same digest pattern as wild type (some mutants not shown). The loop 3 helix deletion strain
had a similar digest pattern, but the relative intensities of the bands were slightly affected. The
digest patterns of the single residue mutants, combined with their retention of iron uptake
functions, confirm that the proteins are surface exposed and in the proper conformation. The
digest pattern of the loop 3 deletion is similar to the pattern displayed by the loop 3 HA epitope
insertion strain described previously (250). Although the digest pattern suggests that the TbpA
conformation may be slightly altered in these latter two mutants, no new digestion products
were visualized, and proteolysis demonstrates the TbpA proteins are indeed surface exposed.
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Figure 3.11. TbpA mutations do not prevent surface exposure.
Whole, iron-stressed gonococcal cells were exposed to trypsin for 0, 10, 20, and 30 minutes
after which the reaction was stopped by addition of aprotonin. Lanes labeled “X” were not
treated with trypsin. Bacteria were pelleted, and subjected to SDS-PAGE followed by transfer to
nitrocellulose. Western blots were probed with polyclonal TbpA antibody. Full length TbpA is
100kDa. Trypsin cleavage resulted in TbpA fragments of approximately 95 and 55 kDa.
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Figure 3.11. TbpA mutations do not prevent surface exposure
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III. Discussion
TbpA is considered a viable vaccine candidate for prevention of gonococcal infection, due to
its lack of antigenic and phase variation (261), but there have been complications in developing
a successful vaccine. One issue is that, when used as an immunogen, TbpA alone results in a
relatively weak immune response (232, 262). In addition, although TbpA is required for
initiation of human infection (198), it is not required for survival in the estradiol-treated female
mouse model used for vaccine development (73, 263), complicating efforts to target TbpA
alone (for review see (236)). Some challenges to vaccine development were to be expected
when the primary resource was a 2D topology map of TbpA that took over a decade of work to
refine (264). However, there were hopes that once a 3D structure was developed, it would
greatly accelerate the ability to target key regions of TbpA for vaccine development. With the
resolution of the TbpA crystal structure from N. meningitidis in 2012, which largely confirmed
the 2D topology model in the gonococcus, it was anticipated that this data would be invaluable
for gonococcal studies due to the high sequence homology between the related pathogens.
After solving the structure, Noinaj et al. developed antibodies against four small, predicted
functional domains of the protein (190). In recombinant E. coli, these antibodies showed some
promise, although the sera had to be used at high concentrations (1:20) to demonstrate any
inhibitory effect. These crystal structure derived epitopes showed potential, but they were not
tested in the native bacterium.
We set out to bridge the gap between characterizing antibody interactions with
recombinant E. coli versus N. gonorrhoeae. Using the antibodies from the previously mentioned
study, we determined that when applied to the gonococcus, these antibodies did not interact
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with TbpA in the same manner that they did for recombinant E. coli. In fact, the anti-peptide
antibodies were twice as effective against E. coli in some cases, and even then demonstrated
only modest ability to block TbpA-ligand interactions. It is possible these antibodies did not
block ligand well because the immunogens were too small to elicit robust titers. We have
determined previously that antibodies raised against larger loop antigens for loops 2, 4, and 5
can bind to the gonococcal surface (265). However, even these longer loop-specific antibodies
were unable to block Tf binding (265). Another possible explanation for why the original loop
antibodies did not block TbpA-ligand interactions is that the linear presentation of the peptide
immunogens may not have represented the structural complexity of the loops in their native
context, resulting in decreased binding to folded TbpA. These unanticipated findings
demonstrate the complexity of specifically developing immunogens from the crystal structure
alone. However, with modification to length, composition, and conformation, we were able to
make second generation TbpA loop specific antibodies that we predicted could overcome some
of the limitations of the original loop antibodies. Although similar levels of ligand blocking were
demonstrated with these new antibodies on the gonococcal surface, there was an observed
decrease in efficacy against E. coli. This finding presents new questions about effective antibody
development. Further work needs to be done to investigate the roles of various loops, explore
how peptide presentation translates to antibody efficacy, and determine why some antibodies,
like the holo-TbpA antibodies, are effective against E. coli, but not the gonococcus. Despite
these lingering questions, this work’s innovative approach to development of peptide-specific
antibodies will provide helpful insights for future work targeting the Tbps for vaccine
development.
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After addressing antibody function on the gonococcal surface, attention was shifted to
further exploring the structure-function relationships predicted for TbpA. Based upon our
previous studies, we concluded that an HA tag insertion into loop 3 completely inactivated
TbpA function (250). The TbpA crystal structure also shows that the loop 3 helix seems to fit
inside the C-lobe cleft of Tf, in close proximity to the iron chelation center. Within this chelation
center, there is a triad of pH sensing residues (K534, R632, and D634) that are predicted to
control iron binding and release. TbpA residue K359 is adjacent to this triad, and was
hypothesized to disrupt the charge balance enough to release the iron from the coordinating
residues. To test this hypothesis, mutations were made to change each of the polar residues on
the helix. A complete helix deletion was also generated. Gonococcal strains that had these
TbpA mutations with and without the co-receptor, TbpB, were created so that effects on TbpA
could specifically be evaluated. Finally, the phenotypes of the mutants were determined in the
two steps of the TbpA-Tf interaction: ligand binding and iron extraction/internalization.
We assessed mutant TbpA-Tf binding using ELISAs, and determined that in the absence of
the co-receptor there was a moderate reduction in ligand binding. The helix deletion strain,
however, suffered a severe reduction in binding, suggesting the entire helix domain is
important for ligand interaction. Although single residue mutations had only modest effects,
there are 81 predicted TbpA residues that interact with Tf, so it was unlikely that any single
residue mutation would completely abrogate TbpA-Tf binding. Although interference with
ligand binding was a promising outcome, assessing iron uptake was the primary objective, and
more likely to be affected by the selected mutations.
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We proceeded to analyze the abilities of the mutant TbpAs to utilize Tf bound iron using a
radiolabeled iron uptake assay. As predicted, the iron uptake function was impacted more than
ligand binding, supporting our hypothesis that Loop 3 helix polar interactions are involved in
iron release from its chelation center in Tf. Mutating the polar residues all along the helix had
substantial negative effects, but certain residues stood out as more important than others. As
mentioned previously, it was predicted that the lysine residue at TbpA position 359 was the key
residue in contributing to iron release. Indeed, when this residue was mutated to residues of
opposite or no charge, some of the most substantial decreases in iron uptake occurred.
Surprisingly, the greatest decrease in protein function came from an additional negative charge
at residue 360. Together, these data would suggest that a positive charge presence is required
in the Tf C-lobe cleft to cause iron release and utilization. Additionally, changing the identity of
all tested residues along the length of the helix caused greater than 50% reduction in protein
function. This implies that all of these residues are required to position the helix properly in the
cleft for optimal functioning. This concept is further supported by the loop 3 helix deletion
strain, which was incapable of iron internalization.
Although it is easiest to see defects when evaluating TbpA alone, this is not a realistic view
of how the Tf iron acquisition system functions in the gonococcus. Indeed, no TbpB deficient
gonococcal strains have ever been identified. Therefore, we repeated the radiolabeled iron
uptake assays in the presence of the co-receptor TbpB with some of the best and worst
performers from the TbpA-only iron uptake study. In each case, a dramatic recovery of iron
uptake function was observed, although uptake function in some mutants was still significantly
lower than wild-type. This might have been anticipated for several reasons. First, previous
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studies have demonstrated that the Tf receptor complex is relatively insensitive to point
mutations (190, 258). Second, it has been hypothesized that TbpB causes a closure of the
chamber formed between Tf and TbpA, so that free iron cannot diffuse away. And third, it is
predicted that TbpB is largely responsible for the release of deferrated Tf. Together, this
suggests that even if the Tf-iron transporter is greatly handicapped, TbpA can still accomplish its
goal of sufficient nutrient acquisition if the co-receptor is present. The exception to this, again,
is the helix deletion strain. This TbpA mutant has almost no capacity to internalize iron, even in
the presence of TbpB. Because this mutant binds Tf at less than 10% of WT levels, it is difficult
to assess whether TbpB truly cannot compensate for the defect, or if the 3-part complex never
forms. In sum, these findings highlight the importance of the loop 3 helix motif in iron
acquisition, and demonstrate the likely importance of simultaneously targeting both Tf
receptors to achieve maximal inhibition.
We were able to partially inactivate the Tf receptor complex with mutations, therefore we
next tested whether these mutations similarly inhibited gonococcal growth on hTf as a sole iron
source. When the mutant strains were grown on CDM-Tf agar plates, we found that all single
residue mutants with and without TbpB could grow. The only strains unable to grow were the
helix deletion strains. These findings suggest that even at TbpA function as low as 15% of WT,
the gonococcus is able to survive on poorly saturated Tf as a sole iron source. The helix deletion
strains demonstrate that there is a level at which growth cannot be sustained, and the level
exists somewhere between 3-15% TbpA function. These data are novel in that they are the first
to report the degree to which TbpA needs to be impaired in order to prevent growth on hTf.
These data also provide new insights into the function of the loop 3 helix and further indicate
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that while residue K359 is important for TbpA function, other helix residues apparently play
equally important roles.
We confirmed that the mutants constructed in this study were still surface exposed and
folded properly. Using a proteolytic accessibility assay, it was demonstrated that all the single
residue mutations, both in the presence or absence of TbpB, displayed the same cleavage
patterns as the parental strain. The helix deletion strain was protease accessible, demonstrating
that it was surface exposed, but the relative intensities of the cleavage products were altered.
This suggests that the presentation might be slightly different compared to the wild-type
protein. Indeed, previous insertions into loop 3 demonstrated the same protease-sensitivity
pattern, showing that moderate perturbation to the loop potentially alters its conformation
slightly.
This study demonstrates that, in the case of TbpA, structure-driven epitope selection for
vaccine development does not necessarily translate into successful binding to the surface of the
native bacterium. We found that loop 3 was poorly immunogenic, supporting the hypothesis
that the gonococcus has evolved to keep functional domains from being targeted by the
immune system (233). We also clearly demonstrated that the loop 3 helix plays a critical role in
protein function, both in binding and in iron extraction/internalization. Of note, the function of
the loop 3 helix was not solely dependent on K359 as predicted. Instead, all of the residues
targeted for mutagenesis play important roles in TbpA function. We determined that the coreceptor TbpB can largely compensate for mutations in TbpA, and that provision of a functional
TbpB is sufficient to allow growth even at greatly reduced TbpA functionality.

91

The studies described in the current report represent the first gonococcal structure-function
characterization of the Tf receptor system since it was crystallized from N. meningitidis in 2012.
The resolution of these crystal structures provides critical information to the field and serves as
a foundation for studies, like those described herein, and represent the start of a new era in the
pursuit of vaccine development and therapeutic intervention efforts targeting these proteins.
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Chapter 4: Development of a Platform to Characterize Gonococcal HpuA StructureFunction Relationships

I. Introduction
Nearly two thirds of iron in the human body is sequestered in hemoglobin (Hb) inside of
human erythrocytes (266). Upon hemolysis, tetrameric Hb dissociates into dimers that are
quickly bound by haptoglobin (Hp), which serves to protect the body from Hb induced oxidative
stress, and to facilitate Hb clearance by the reticuloendothelial system (178, 267, 268). In order
to gain access to this vast iron reservoir, the Neisseriaceae family expresses two hemoglobin
receptor systems, HpuAB, and HmbR. Interestingly, while both receptors can extract heme from
Hb for use as an iron source, only HpuAB can extract heme from the Hb:Hp complex (202, 205).
HpuAB is also the only functional Hb receptor in N. gonorrhoeae, as all published gonococcal
chromosomes contain a premature stop codon in HmbR (204, 210, 269). This is in contrast to N.
meningitidis, where 99% of disease associated meningococcal strains possess at least one of the
Hb receptor systems, and strains responsible for the highest rates of disease encode both (270).
In gonococcal clinical isolates, HpuAB is most often phase off, but expression has been
demonstrated to increase during early stages of menstruation in women, when Hb is in greater
supply (203, 257). Meningococcal isolates are far more likely to express Hb receptors, with 91%
of disease isolates and 71% of carriage isolates found to express at one or both receptors (270272). These findings seem to suggest that there may be an association between Hb utilization
and disease, but other studies have demonstrated that transferrin still remains the main source
of iron during meningococcal growth in human blood (273). Regardless of which iron source is
93

most used, an HmbR knockout strain of N. meningitidis displayed attenuated infectivity in an
infant rat model of infection, demonstrating the importance of Hb utilization (269).
Due to the importance of hemoglobin for meningococcal infection, and its selected use in
gonococcal infection, the HpuAB receptor appeared to have potential to be included in a
multivalent vaccine. Further investigation, however, demonstrated that the sequences of both
proteins across Neisseria species are under significant immune selection due to their highly
exposed localization (274), resulting in rapid evolution through genetic change to thwart host
defenses (84). This finding was further supported by a study that demonstrated antibodies
directed against HmbR and HpuA were reactive to the cell surface, but incapable of initiating a
bactericidal response (273). Together, these findings would suggest that Hb receptors have low
vaccine potential due to non-productive responses and concerns about cross protectiveness.
The hemoglobin receptors of Neisseria gonorrhoeae have been the subject of far less
investigation than the other TonB dependent iron uptake systems. Despite the limited vaccine
potential of HpuAB, there are still many questions about Hb receptor structure-function
relationships and mechanisms of heme uptake. To help address these questions, the crystal
structure for HpuA from Kingella dentrificans (Kd), a member of the Neisseriaceae family, was
recently published (275). A model of HpuA from N. gonorrhoeae (Ng) based on the Kd crystal
and a partial crystal of the C-terminus of Ng HpuA was also constructed, allowing for
comparisons to be made across species. This study provided several new pieces of information
essential to understanding this receptor system. For the first time it was demonstrated the
HpuA alone can interact with human Hb, whereas it was already known the HpuB could interact
with Hb and Hb:Hp (276). It has also been demonstrated that HpuA binds the Hb dimer in a
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different region from the Hp binding site (277), suggesting that HpuA could also bind Hb:Hp,
but would not directly bind apo-Hp(275). Most notably, mutations were constructed to probe
deletions and point mutations in predicted regions of Kd HpuA-Hb interaction. Although the
assays were qualitative, clear decreases in ligand binding were demonstrated in several
deletions and mutations. These data set the foundation to specifically probe similar interactions
between Ng HpuA and Hb in the native bacterium.
In collaboration with Dr. Stephen Hare, studies were initiated to test similar HpuA
mutations in the gonococcus. Mutations were designed based on findings in Dr. Hare’s previous
work (275), and he shared plasmids with our lab that contained mutated copies of hpuA
(pVCU173-189). In total, 13 point mutations and 3 deletions were constructed in homologous
regions to mutations in Kd HpuA to further evaluate the Ng HpuA structure function
relationships (Fig. 4.1). In order to initiate these studies, a platform needed to be developed to
characterize these mutants, which require three preliminary steps. First, an hpuA- strain needed
to be created in order to test mutant copies of the gene. Second, a complementation vector
needed to be generated that had all the necessary components for proper hpuA expression.
And lastly, the mutant gene copies needed to be cloned into the complementation vector.
These steps have been completed, as described below, and the platform is now available to
phenotypically characterize the HpuA mutants.
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Figure 4.1. Structural models of HpuA.
Crystal structure of HpuA in complex with hemoglobin (Hb) from closely related Kingella
dentrificans (Kd) and superimposed model of HpuA-Hb from Neisseria gonorrhoeae (Ng). HpuA
residues predicted to be sites of Hb interaction are highlighted in blue.
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Figure 4.1. Structural models of HpuA
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II. Results
A. Construction of HpuA- strain
i. Insertional inactivation of hpuA
The inactivated hpuA plasmid (pVCU253) was constructed in two steps with the In-fusion HD
cloning kit (Clontech), which uses proprietary enzymes to recombine PCR products with
linearized plasmid DNA when they share 15 bp of homology at their ends. First, the phase-on
locked, mutant hpuA R299A from pVCU185 was amplified with primers oVCU823 and oVCU824
(Fig. 4.2). Using the In-fusion kit, this gene was inserted into SmaI digested pVCU403, creating
plasmid pVCU252. Then, the aphA-3 kanamycin resistance cassette was amplified from pUC18K using primers oVCU825 and oVCU826. The aphA-3 PCR product was inserted into the
PpuMI site on pVCU252, creating pVCU253.
ii. Gonococcal transformation
To create the hpuA- strain (MCV140), pVCU253 was digested with ScaI-HF, and an FA19 Hb+
strain was transformed with the linearized DNA. Gonococcal transformants were screened by
PCR amplification of hpuA to determine that only the aphA-3 inactivated form of the gene was
present. In addition, the hpuA PCR products were digested with BslI, which digests the wildtype but not the mutated, locked phase-on slip-strand region. This screening step was
necessary to ensure the downstream gene, hpuB, would always be transcribed during
phenotypic characterization.
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Figure 4.2. Plasmid construction of inactivated hpuA gene.
The inactivated hpuA was constructed in two steps. First, HpuA R299A from pVCU185 was
inserted into SmaI digested pVCU403, creating pVCU252. Subsequently, the aphA3 cassette
from pUC18K was inserted into PpuMI digested pVCU252, creating pVCU253.
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Figure 4.2. Plasmid construction of inactivated hpuA gene

100

B. Complementation vector construction
To construct a complementation vector to ectopically express mutant copies of hpuA, a
ribosomal binding site (RBS) was added to plasmid pKH37 (252). To do this, annealed DNA
oligomers (oVCU814 and 815) coding for an 8 base pair (bp) RBS were inserted into PacI and
SmaI digested pKH37, creating pVCU234 (Fig. 4.3).
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Figure 4.3. Construction of complementation vector.
A ribosomal binding site was added to pKH37 by digesting the plasmid with PacI and SmaI, and
inserting annealed oligomers oVCU814 and oVCU815 between the restriction sites. The RBS
region of the oligomers is underlined.
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Figure 4.3. Construction of complementation vector

Image adapted from (278)
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C. Mutant hpuA insertion into complementation vector
Initially, hpuA was cloned into pVCU234 using traditional digestion and ligation methods.
hpuA containing plasmids pVCU174-6 and pVCU187-9 were digested with EcoRI, blunt-ended
with DNA Polymerase I Large (Klenow) Fragment, and subsequently digested with XhoI. The
complementation vector pVCU234 was digested with SmaI and XhoI, and the hpuA PCR
fragment was ligated in between those restriction sites. Blunt-end ligation resulted in low
cloning efficiency, so In-fusion HD cloning was adopted to optimize the cloning process. In this
approach, pVCU234 was digested with SmaI only. Mutant copies of hpuA were amplified from
plasmids pVCU173 and pVCU185 with primers oVCU821 and oVCU822. The digested vector and
PCR products were mixed together with the proprietary In-fusion enzymes per kit instructions,
and the DNA overlap regions were recombined to create a complete plasmid with one
directional PCR product insertion (Fig. 4.4).
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Figure 4.4. Cloning mutant hpuA into pVCU234.
In order to clone mutant copies of hpuA into the complementation vector (pVCU234), In-fusion
primers oVCU821 and oVCU822 were used to PCR amplify the mutant hpuA genes, and the
genes were inserted into SmaI digested pVCU234.
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Figure 4.4. Cloning mutant hpuA into pVCU234

Image adapted from (278)
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III. Discussion
With the creation of MCV140 and the complementation plasmids made from pVCU234, the
platform to test mutations in hpuA is fully developed. After MCV140 is transformed with the
complementation plasmids, mutant copies of hpuA will insert ectopically between the lctP and
aspC genes, and will be under control of the lac promoter. Since the aphA3 insertion in wildtype hpuA locus is non-polar and the native slipstrand region of hpuA is locked in the on
position, native levels of HpuB will be produced. Because the ectopic locus of hpuA will be
overexpressed, a wild-type copy of hpuA will also be ectopically inserted to serve as the positive
control during experimentation. Conditions that are un-induced should serve as the negative
controls. If there is basal expression from the ectopic site without the addition of IPTG, MCV140
could serve as an additional negative control.
With regards to characterizing the mutant HpuA proteins, ligand binding and growth on
hemoglobin should be assessed. Hemoglobin binding assays could be performed similar to the
Tf binding ELISAs described previously, with the exception that bound hemoglobin will need to
be detected by antibodies, which could then be detected colorimetrically. Hemoglobin
dependent growth should be characterized with hemoglobin as a sole iron source both in solid
media and in liquid culture. Solid phase growth could be assessed on varying concentrations of
hemoglobin as described for the solid phase transferrin dependent growth. Liquid culture
analysis should evaluate OD600 readings of gonococcal cultures in microtiter dishes over several
hours to determine if hpuA mutants have growth handicaps relative to the positive control.
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Chapter 5: Small Molecule Inhibition of TbpA

I. Introduction
In addition to pursuing the transferrin receptors as vaccine targets, they are also considered
potential drug targets. Given that iron is an essential micronutrient, depriving the gonococcus
access to host derived iron sources could serve as either a standalone antimicrobial modality or
an adjunctive mechanism to enhance the antimicrobial effects of other drugs. Since transferrin
is considered the primary iron source for the gonococcus in vivo, and the Tbps are the best
studied of the gonococcal iron acquisition systems, it was hypothesized that novel drugs could
be developed to inhibit the use of transferrin as an iron source.
This project required complex in silico analysis of the TbpA crystal structure to select
possible regions for drug targeting, as well as selection of small molecules to use as the
inhibitors. Once compounds were selected, preliminary analysis of TbpA-Tf inhibition would be
carried out through whole cell transferrin binding ELISAs.

II. Results
In order to identify potential binding sites on TbpA, and to screen molecules that could bind
those sites, collaboration was established with Dr. Glen Kellogg in VCU’s department of
Medicinal Chemistry. Using the co-crystal structure of TbpA in complex with human Tf, at least
two binding sites were identified for small molecule inhibitor studies (Fig. 5.1-5.4). In order to
select molecules that would bind those pockets, small molecule databases were screened for
compounds that share structural similarity with the Tf amino acids that bind those locations
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(Fig. 5.2). Compounds were selected based on their hydropathic interactions (HINT) scores,
which describe and quantify all interactions in the biological environment. The HINT score
factors in all types of interactions, including the coulombic, hydrogen bond, and hydrophobic
interactions which are expected to be found between molecules. The HINT score also encodes a
free energy force field, and thus includes entropy and solvation/desolvation, besides the other
enthalpic terms. Higher HINT scores indicate more favorable interactions between the molecule
and TbpA. An example of a small molecule with high HINT score docked to TbpA is shown in Fig.
5.4.
After screening small molecule databases, 15 compounds were selected for preliminary
evaluation. Due to lack of solubility information, the compounds were dissolved in DMSO at a
concentration of 10 mM. Compounds were applied to whole cell ELISAs as described above at
50 μM concentration prior to application of HRP-labeled transferrin. PBS and DMSO conditions
served as the negative controls, and excess unlabeled transferrin (Comp), a competitive
inhibitor of HRP-Tf, served as the positive control. Preliminary results are represented in Fig.
5.5, where compound 7 demonstrated approximately 20% inhibition of Tf binding. Compound 7
had reproducible, modest inhibition of the TbpA-Tf interaction; however, the other 12 tested
compounds failed to demonstrate substantial, reproducible inhibition. Indeed, several
compounds seemingly increased the binding of HRP-Tf. Optimization of this project is ongoing.
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Figure 5.1. Location of binding site I.
TbpA is shown in cartoon representation colored by secondary structure (α-helices in red, βsheets in yellow and loops in green), Tf is shown in stick representation in grey and binding site
I location is shown in pink. A) side view and B) top view (PDB ID 3V8X).
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Figure 5.1. Location of binding site I
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Figure 5.2. Binding site I residues.
TbpA residues forming binding site I in grey, with colored secondary structure (α-helices in red,
β-sheets in yellow, and loops in green). ASP416 and ASN417 from Tf are shown in magenta
(PDB ID 3V8X).
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Figure 5.2. Binding site I residues
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Figure 5.3. Location of binding site II.
TbpA is shown in cartoon representation colored by secondary structure (α-helices in red, βsheets in yellow and loops in green), Tf is shown in stick representation in grey and binding site
II location is shown in pink (PDB ID 3V8X).
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Figure 5.3. Location of binding site II
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Figure 5.4. Binding site II residues.
TbpA Residues forming binding site II colored by secondary structure (α-helices in red, β-sheets
in yellow and loops in green). Candidate compound ZINC04896026 shown in grey (PDB ID
3V8X).
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Figure 5.4. Binding site II residues
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Figure 5.5. Preliminary inhibitory data.
Small molecules were applied to whole cell ELISAs prior to the application of HRP-Tf. Tf bound
to the gonococcal surface was detected colorimetrically, and data was standardized to the
DMSO positive control. All conditions were performed in triplicate. This is a representative
image of preliminary inhibitory data.
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Figure 5.5. Preliminary inhibitory data
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III. Discussion
Although these results are preliminary, there is evidence that some of the drugs in the first
set have the capacity to limit TbpA-Tf interactions, even if the effect is modest. Once initial
compounds that have inhibitory effects are identified, the molecular structures can be subtly
changed and retested for improved or altered activity. It should also be considered, however,
that transferrin is not the only usable iron source available to the gonococcus during the course
of human infection. Accordingly, similar efforts should be directed at other acquisition systems,
namely the lactoferrin receptors, given lactoferrin is released by neutrophils as part of the
innate immune response (155, 279). Since LbpA and TbpA have approximately 41% sequence
identity and 67% sequence similarity, it is predicted that these proteins adopt similar structure
and interact with their ligands in similar ways (280). This suggests there is a possibility that one
drug may be able to inhibit both receptor systems, which warrants further investigation. If one
drug is not found that inhibits both receptors, combinations of drugs should be evaluated
against gonococcal growth to determine whether inhibiting multiple iron acquisition pathways
is advantageous for attenuating gonococcal growth.
Compounds designed to inhibit iron acquisition represent a novel mechanism for
antimicrobial agents, and they could also be species specific. These drugs are designed against
specific proteins, gonococcal TbpA in this case, so it is predicted that there should be little
effect on other species. Even if these drugs are cross reactive, only members of the families
Neisseriaceae, Pasteurellaceae, and Moraxellaceae are capable of acquiring iron from host ironbinding proteins (281). Tf binding inhibitors, therefore, could have activity against a range of
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pathogens, without impacting the native gut flora, which predominately use siderophores for
iron acquisition.
Antimicrobial resistance is often accelerated through misuse and overuse of current
antibiotics (282, 283). The mechanism of action and protein specific nature of iron uptake
inhibition drugs would, by default, reduce the spectrum of their activity. Although this presents
some limitation in their clinical use, it could also contribute to slower resistance development.
This is especially important given that commensal species often develop resistance genes, and
through the natural competence of gonococci, rapidly transfer these genes to pathogenic
strains (284-286). With no single agent therapy remaining to tackle gonococcal infection, and
growing resistance to many classes of current antimicrobials, iron acquisition inhibitors
represents a new mechanism for the treatment of gonococcal infections that warrants further
investigation.
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Chapter 6: OSU-03012 and PDE-5 Inhibitor Antimicrobial Activity

I. Introduction
OSU-03012 (OSU), a derivative of the COX2 inhibitor celecoxib, was initially designed as a
cancer therapy, since COX2 inhibition had been shown to decrease growth and increase tumor
specific cell death (287-290). After its development, it was determined that OSU lacks COX2
inhibitory activity (291, 292), but was initially thought to inhibit PDK-1 in the PI3K pathway
(291). However, later studies demonstrated that OSU toxicity was due to enhanced
endoplasmic reticulum (ER) stress signaling and down regulation/reduced half life of ER and
plasma membrane localized HSP70 family chaperone GRP78/BiP/HSPA5 (293, 294). It was
already known that prokaryotic cells have a GRP78 homologue, DNA K, and that this protein
plays an essential role as a chaperone for proteins like RecA, which is essential for DNA
maintenance and repair (295). Therefore, it was hypothesized that OSU may have antibacterial
activity, especially during times of rapid cellular division when protein production is high. This
hypothesis was supported by the discoveries that GRP78 is essential for viral replication during
infection with human immunodeficiency virus (296), respiratory syncytial virus (297), measles
virus (298), rotavirus (299), influenza virus (300), and Ebola virus (301, 302), and that OSU
treatment can be down-regulate receptors for these viruses and also inhibit viral reproduction
(303).
It was hypothesized that OSU has antimicrobial properties, and that combining OSU with
other drugs might amplify its effects. Since bacterial cells have phosphodiesterases (304), and
PDE inhibitors have been shown to increase chemotherapy effects in cancer (305, 306), PDE-5
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inhibitors sildenafil and tadalafil were applied to gonococcal cultures with OSU. In order to test
synergy with other known antibiotics, OSU was also applied to gonococcal cultures in
combination with ceftriaxone, azithromycin, or ciprofloxacin.

II. Results
A. OSU and PDE-5 inhibitors’ anti-microbial properties for lab strains
Lab strains FA19 (Fig. 6.1) and FA1090 (data not shown) were grown in the presence of OSU
and PDE-5 inhibitors alone and in combination. OSU was applied at concentrations ranging from
2-8 μM when applied alone, while sildenafil (SIL) and tadalafil (Tad) were used at 4 μM. When
used in combination, OSU was applied at 2 μM with either 4 μM SIL or TAD. Chloramphenicol
(Cm), a conventional bacteriostatic antibiotic, was also applied at 34 μM in order to provide a
reference for the effects of the investigational drugs. The investigational drugs were solubilized
with DMSO, so vehicle (V) controls were added to determine the effects of solvent in drug
conditions. CDM only growth was used as the positive control.
OSU at 2 μM had no effect compared to vehicle controls, however, 4 and 8 μM OSU
caused rapid gonococcal cell death within the first hour. Compared to the Cm control, these
results suggest that OSU alone has bactericidal properties. Sildenafil and Tadalafil had no effect
compared to the vehicle control when used alone. However, when non lethal doses of OSU (2
μM) and SIL/TAD (4 μM) were combined, gonococcal growth was attenuated. These results
suggest that these drugs have a synergistic effect, and that the addition of a PDE-5 inhibitor can
effectively lower the minimum inhibitory concentration (MIC) of OSU. Of note, when 2 μM OSU
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was added to the Cm control, there was no change compared to the Cm alone condition. This
suggests that these two drugs did not have synergistic effects.
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Figure 6.1 FA19 growth in the presence of OSU and PDE-5 inhibitors.
These data are from a single assay performed in triplicate, which is a representative image of
multiple assays in which gonococcal lab strain FA19 was grown in CDM in a microtiter dish in
the presence of OSU (O), Sildenafil (SIL, S), Tadalafil (TAD, T), Chloramphenicol (Cm), DMSO (V),
or combinations thereof. OD600 measurements were taken at the time of drug application and
then hourly for four hours. Concentrations in μM units are represented by the numbers in the
figure legend adjacent to the drug abbreviation. DMSO percentage represents the
volume/volume ratio with CDM. Each condition was performed in triplicate, and data points
represent the mean ± the SEM.
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Figure 6.1. FA19 growth in the presence of OSU and PDE-5 inhibitors
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B. OSU effects on drug resistant gonococcal strains H041 and F89
After demonstrating that OSU alone is able to attenuate growth in lab strains, and that this
effects is enhanced by PDE-5 inhibitors, the same drug assay was repeated to determine if
recent, multi-drug resistant “super bug” strains H041 and F89 (62, 63) are also susceptible to
the investigational drugs. It was quickly determined that PDE-5 inhibitors, as with the lab
strains, had no effect on superbug growth. In addition, the PDE-5 inhibitors were no longer
synergistic with OSU when applied to the superbug strains (data not shown), leading to the
decision to discontinue there use in future assays. Despite the observation that Sildenafil and
Tadalafil could not impact growth of drug resistant strains, OSU continued to demonstrate its
bactericidal effects in these strains (Fig. 6.2). As observed with the lab strains, 2 μM OSU had no
effect on gonococcal growth, but at doses of 3 μM and above, the drug was rapidly lethal. This
observation was important, because it demonstrated the approximate MIC for OSU. These
assays were also carried out with higher concentration stocks of OSU, limiting the amount of
DMSO in the assay. Vehicle controls (not shown), were identical to the CDM growth condition.
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Figure 6.2. Superbug growth in the presence of OSU.
These are representative images of multiple assays in which gonococcal strains H041 and F89
were grown in the presence of 2 and 3 μM OSU in microtiter dishes. OD600 measurements were
taken at the time of drug application and then hourly for four hours. Each condition was
performed in triplicate, and data points represent the mean ± the SEM.
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Figure 6.2. Superbug growth in the presence of OSU
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C. OSU has synergy with conventional antibiotics
Since synergy was observed between OSU and the PDE-5 inhibitors in lab strains, but not in
superbug strains, it was hypothesized that OSU might enhance the effects of conventional
antibiotics, even those whose clinical use has been discontinued due to gonococcal resistance.
To test this hypothesis, drug resistant gonococcal strains were grown in the presence of MIC
and sub-MIC levels of antibiotics alone and in combination with sub-MIC levels of OSU. F89 and
H041 have approximately equivalent MICs for ciprofloxacin (Cip) and azithromycin (Az),
however the ceftriaxone (Cef) MIC for H041 is double that of F89 (61, 63). Interestingly, the
reported MICs for Cef and Cip were valid in our assay, but the strains seemed more sensitive to
Az than expected. Accordingly, the Az dose was titrated down until a level that was not
inhibitory on its own was reached, approximately 10 fold below the reported MIC.
These assays, carried out similarly to those above, demonstrated that the combination of
Cef and OSU has a robust synergistic effect in both superbug strains, and resulted in rapid cell
death starting at approximately two hours (Figs. 6.3, 6.4). A similar synergistic effect starting at
two hours was observed for OSU and Az, but in contrast to Cef, the effect was not bactericidal.
Lastly, the combination of OSU and Cip demonstrated modest synergy, which was more
pronounced with H041 than with F89. This phenomenon may be the result of higher Az
sensitivity in F89, as the Cipro alone condition were highly effective at attenuating growth. In
sum, these assays demonstrate that OSU has synergy with three independent classes of
antibiotics within two of the most drug resistant isolates of N. gonorrhoeae known to date.
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Figure 6.3. F89 Growth in the presence of OSU and conventional antibiotics.
These are representative images of multiple assays performed in triplicate in which gonococcal
strain F89 was grown in the presence of MIC and sub-MIC levels of Cef, Az, and Cip, with or
without 2 μM OSU in microtiter dishes. OD600 measurements were taken at the time of drug
application and then hourly for four hours. Each condition was performed in triplicate, and data
points represent the mean ± the SEM.
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Figure 6.3. F89 Growth in the presence of OSU and conventional antibiotics
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Figure 6.4. H041 Growth in the presence of OSU and conventional antibiotics.
These are representative images of multiple assays in which gonococcal strain H041 was grown
in the presence of MIC and sub-MIC levels of Cef, Az, and Cip, with or without 2 μM OSU in
microtiter dishes. OD600 measurements were taken at the time of drug application and then
hourly for four hours. Each condition was performed in triplicate, and data points represent the
mean ± the SEM.
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Figure 6.4. H041 Growth in the presence of OSU and conventional antibiotics
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III. Discussion
The data presented here demonstrate that OSU alone has antimicrobial effects against lab
strains and drug resistant clinical isolates of N. gonorrhoeae. These data support the hypothesis
that OSU has antimicrobial effects at concentrations that are physiologically achievable in
humans; however, the therapeutic window is narrow. OSU rarely achieved serum
concentrations above 4 μM in human clinical trials (294), suggesting that microbial resistance to
OSU would render the drug ineffective almost immediately. Several pairings were tested
between OSU and currently used drugs to determine if synergistic effects exist that could
decrease the amount of OSU necessary for antimicrobial effects, thus extending its therapeutic
window. This line of inquiry had the potential to discover antimicrobial effects in drugs
designed for other purposes, as well as resurrect the utility of certain antimicrobials that are no
longer capable of eliminating gonococcal infection when used alone.
PDE-5 inhibitors were chosen for use with OSU based on observations that they enhanced
effects of standard of care chemotherapy drugs in CNS, gastrointestinal, and genitourinary
cancers (305, 306), and the observation that prokaryotic cells have cyclic di-GMP (307), which is
regulated by phosphodiesterases (308). Indeed, cyclic di-GMP has been shown to be a regulator
of bacterial virulence (309, 310), enhancing interest in it as an antimicrobial target. There does
not appear to be any data in the literature that directly shows that PDE inhibitors affect
bacterial phosphodiesterases, therefore, the potential of these drugs potential was tested.
Although PDE-5 inhibitors moderately attenuated gonococcal growth in the presence of
OSU when applied to lab strains, they did not display the same effect in drug resistant strains.
This suggests that PDE-5 inhibitors have very modest effects in bacteria. This result is not
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surprising, given that PDE-5 inhibitors have mixed effects in the literature when applied to
bacteria. One study found that non-specific phosphodiesterase inhibitors could increase
sensitivity to gentamicin in several bacteria in vitro, but this effect was specifically not
attributable to the PDE-5 inhibitor sildenafil, and could not be attributed to any PDE-specific
inhibition that was tested (311). Another study in a mouse model of tuberculosis found that
PDE-3 and 5 inhibition resulted in quicker clearance of infection, but PDE-4 inhibition led to
accelerated time to death (312). Yet another study suggests that PDE-5 inhibitors actually
reduced the activity of ciprofloxacin against a wide array of bacteria during disc diffusion assays
(313). Given these varying results, it is hard to know what effects PDE inhibitors have on
prokaryotic cells. There are possible confounders in that in vitro assays may yield different
results than in vivo experiments based on host-pathogen interactions. Accordingly, further
studies are warranted to fully investigate the role PDE inhibitors may have in antimicrobial
therapy.
Although the combination of OSU and the PDE-5 inhibitors was not effective in drug
resistant strains of N. gonorrhoeae, there was still potential for OSU to enhance the effects of
conventional antimicrobial drugs. For these assays, drugs with three different mechanisms of
action were chosen. Ceftriaxone, a 3rd generation cephalosporin, produces bactericidal effects
by irreversibly inactivating bacterial transpeptidases responsible for cross-linking peptidoglycan
in the cell wall (314). Without this repair mechanism, cells eventually lyse from osmotic
pressure. Ciprofloxacin, a fluoroquinolone derivative, inhibits bacterial topoisomerases and
promotes DNA cleavage, normally resulting in rapid cell killing (315, 316). Azithromycin, a
macrolide antibiotic, and chloramphenicol possess different mechanisms of action; however
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both inhibit ribosome function (317). Without the ability to synthesize new proteins, these
drugs arrest cell function, leading to bacteriostatic effects. Combining these drugs, with their
varying mechanisms, with OSU allowed for the determination of which, if any, mechanisms of
cell disruption were able to produce synergistic effects.
The cell killing demonstrated with the combination of OSU and ceftriaxone was robust.
Adding two separate bactericidal drugs together was likely to produce bactericidal effects.
However, the ability for this combination to be lethal when used at individually sublethal doses
showed that the two drugs had more than additive effects. One could speculate that because
ceftriaxone inactivates transpeptidases, the resulting cell stress causes an increase in
transpeptidase production. However, OSU likely prevents the proper folding of those additional
proteins, allowing for a lower dose of ceftriaxone to successfully inhibit cell wall repair. In other
words, OSU likely reduces the MIC for ceftriaxone, which until recently was the only remaining
single agent therapy for gonococcal infection. Although ceftriaxone is still a part of the current
gold standard therapy, this finding raised hope that combining OSU with discontinued
antimicrobials might make them therapeutically relevant again.
Azithromycin, the other component of the current gold standard of gonococcal therapy,
also had synergistic effects with OSU. However, the combination resulted in more attenuated
growth, as opposed to cell death. These results suggest that OSU improves the effects of
azithromycin treatment, effectively decreasing its MIC. However, the azithromycin assays left
some questions about the effects of using two drugs that function in the same pathway, protein
synthesis. Fortunately, some additional information can be gleaned from the chloramphenicol
and OSU trials in the lab strain FA19. Because chloramphenicol was used as a bacteriostatic
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control, it was applied at a concentration above the MIC. When OSU was applied in
combination with chloramphenicol, there was no change in cell growth, it remained
bacteriostatic. Given that OSU’s effects lie in both the inability to form functional proteins, and
in the cell stress derived from unfolded proteins, this result is not surprising. Completely
shutting down protein synthesis leaves nothing for chaperones to fold, which completely
abrogates the negative effects of OSU. Taken together, these data suggest that OSU can
decrease the MIC for protein synthesis inhibitor antibiotics, but as protein synthesis is more
inhibited, OSU’s effects decrease. Although this combination could be used to extend the
therapeutic window for protein synthesis inhibitors, the bactericidal effects of OSU are lost,
suggesting that other combinations may be more effective.
Lastly, OSU was applied to gonococci in combination with ciprofloxacin, resulting in minimal
synergy. This is unlike the synergy observed with ceftriaxone, which is also bactericidal.
However, there is no mechanistic reason to assume these drugs would enhance each other, and
H041 and F89 are particularly resistant to fluoroquinolones. It might have been possible for
OSU to cause misfolded protein accumulation during ciprofloxacin induced growth attenuation,
but that does not appear to have been the case. Alternatively, it could be possible that in
addition to preventing DNA replication, ciprofloxacin inhibition of DNA gyrase may reduce rRNA
and possibly mRNA production, resulting in decreases in protein synthesis (318-321). Were this
to occur, OSU effects would be limited in the same way discussed with protein synthesis
inhibitors above. Given these data, it is likely that ciprofloxacin treatment of gonococcal
infection would not significantly be enhanced by the addition of OSU.
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In summary, OSU has bactericidal activity against the gonococcus, and it also enhances the
bactericidal effects of ceftriaxone and the bacteriostatic effects of azithromycin. However, OSU
does not substantially affect the use of ciprofloxacin in killing gonococci. Future studies should
test the effects of the addition of OSU to the combination of ceftriaxone and azithromycin. It is
possible that OSU could enhance antimicrobial activity, but also possible that OSU’s effects
could be limited and azithromycin. Although OSU has initially shown promise in the treatment
of N. gonorrhoeae, as well as other bacteria, parasites, and viruses, its narrow therapeutic
window and issues with drug delivery (303) limit its potential to make it to pharmaceutical
market. However, these data serve as an excellent proof of principal for targeting protein
chaperones as novel drug targets, which certainly warrants further investigation.
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Chapter 7: Summary and Perspectives

With an estimated 800,000 new cases and a financial burden approaching $1 billion per
year in the United States, coupled with the fact that the gonococcus does not elicit protective
immunity, gonococcal infection is a serious public health concern (57, 322). Recent reports of
increasingly drug resistant clinical isolates from around the world have heightened the severity
of this public health issue, as the number of drugs we have left to treat this infection are
dwindling (61-63). The mechanisms the gonococcus employs to resist the effects of
antimicrobial drugs are summarized in Table 5. Indeed, there are legitimate concerns that we
may be entering an era of untreatable gonococcal infection. This concern is reflected by the
Centers for Disease Control and Preventions listing Neisseria gonorrhoeae as an urgent threat
for anti-microbial resistance, making it one of three pathogens in this highest level category of
threat.
In response to the rise of drug resistant N. gonorrhoeae, several new drugs have been
evaluated in clinical trials for the treatment of gonococcal infection. The farthest along in
testing is solithromycin, a fluoroketolide, which is currently in phase III trials. Solithromycin
inhibits protein synthesis by binding the 50S ribosomal subunit, similar to macrolides (323).
During in vitro testing against over 200 gonococcal isolates, there was no documented
resistance to solithromycin, even in strains that are resistant to extended spectrum
cephalosporins (ESCs) (324). The MIC required to inhibit 90% (MIC90) of gonococcal strains was
0.25 μg/mL, similar to ceftriaxone, but MICs were reported up to 32 μg/mL.
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Table 6. Summary of gonococcal drug resistance
Drug Class

Mechanisms of resistance (325)
Alteration of the penicillin binding proteins (PBPs)

Penicillin

Plasmid mediated production of penicillinases
Alterations in drug influx through porin
Alterations in MtrCDE efflux pump expression
Mutations in PBPs

Cephalosporins

Alterations in porin, mediating influx
Alterations in MtrCDE efflux pump expression

Macrolides
Fluoroquinolones

Alterations in the 23S ribosomal subunit
Alterations in the efflux pump expression
Amino acid mutations in topoisomerases II and IV
TetM, which removes tetracycline from the ribosome

Tetracyclines

Alteration in target structure
Alterations in porin, mediating influx
Alterations in MtrCDE efflux pump expression
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GSK2140944, a novel topoisomerase II inhibitor, is currently in phase II trials. This drug has a
mode of action distinct from fluoroquinolones. GSK2140944 stabilizes the topoisomerase-DNA
complex prior to DNA cleavage and generates single strand breaks, whereas fluoroquinolones
stabilize double strand breaks after cleavage (326). In vitro data for this drug is not currently
available. AZD0914, a spiropyrimidinetrione, is also in phase II trials for gonococcal infection.
AZD0914 possesses a novel mechanism of action; it inhibits DNA biosynthesis and enhances
accumulation of double-strand breaks. In a study of 250 gonococcal isolates, the MIC90 for
AZD0914 was 0.25 μg/mL (327). Strains with higher resistances were mapped to alterations in
gyrB, further distinguishing this drug from fluoroquinolones, to which resistance emerges by
alterations to gyrA (328). A fourth drug, delafloxacin, a fluoroquinolone, was until recently also
in phase III trials. Unfortunately, that trial was halted due to an interim review that suggested
that delafloxacin may not be sufficient to adequately treat patients with gonococcal infection
(325). The results of these clinical trials will be eagerly anticipated, but it is important to note
that one of the selection criteria for patients is uncomplicated gonorrhea. It will take time to
determine how these drugs perform in more complex cases, and if they will be active against
highly drug resistant strains in vivo.
In addition to these drugs which have entered clinical trials, there are several more with in
vitro data suggesting they may be viable therapies. However, most of the drugs are from classes
to which the gonococcus has already started to develop resistance (325). New drugs from old
drug classes could have the potential for the development of rapid resistance to these drugs,
suggesting they will not be clinically useful for a long span of time. Although there is value in
extending our treatment options in the short term, there is still a need for the discovery of
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novel drug targets, and ultimately, a preventative vaccine. The studies described here were
performed in an effort to probe new targets for antimicrobial and vaccine development.
TonB dependent transporters have several criteria that make them ideal drug and vaccine
targets: they are virulence factors known to contribute to gonococcal pathogenesis, they are
not subject to antigenic variation, and they are essential for iron and possibly other metal
acquisition. Given their therapeutic potential, we wanted to further investigate TbpA. This
study began with attempts to reproduce preliminary evidence that antibodies developed
against TbpA surface exposed loops were capable of substantially inhibiting TbpA-Tf interaction
(190). We obtained the antibodies from the preliminary study, and also attempted to make
optimized loop antibodies. Despite promising results in recombinantly expressed TbpA, we
were unable to produce similar antibody mediated inhibition of the TbpA-Tf interaction on the
surface of the gonococcus. These data suggest that small peptide fragments, at least from
TbpA, are unlikely to be successful vaccine candidates. We also probed the structure function
relationship of the TbpA loop 3 helix, in efforts to validate the hypothesis that it was a key motif
involved in iron release from Tf. Although there was no single residue responsible for iron
release from Tf, our data suggests that the loop 3 helix, as a whole, is critical for Tf binding and
iron uptake.
Our studies demonstrate that more complex approaches will be needed in order to develop
an efficacious, protective vaccine against the Tbps. Despite the fact that the Tbps elicit minimal
antibodies during natural infection (262), studies have shown that when applied as
immunogens in animals, the Tbps are capable of eliciting immune responses that are
bactericidal and cross protective (232, 237). Future steps towards developing a Tbp vaccine
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formulation may require inactivation of ligand binding functions of TbpA, as recent work has
shown that decreasing host ligand binding by bacterial proteins increases the effectiveness of
the immune response. The proposed mechanism is that naked bacterial proteins expose more
epitopes to immune cells than ligand bound proteins, allowing antibodies to be more effective
at blocking epitopes that would exist between the ligand and receptor. In support of this
hypothesis, Beernink et al. demonstrated that ligand-binding deficient fHbp from N.
meningitidis was as immunogenic as the wild-type protein but produced higher serum
bactericidal activity (SBA) titers when introduced to transgenic mice expressing human fH (45).
Rossi et al. went on to investigate sub-family A fHbp, which has two distinct point mutations
that decrease fH binding. Immunization with this protein led to significantly higher IgG titers
and SBA responses in human fH transgenic mice (329). The phenomenon of ligand binding
resulting in decreased immunogenicity was also seen to a lesser degree in rhesus macaques
(330).

Recently, similar results were described for TbpB in Haemophilus parasuis (259),

suggesting this approach may be applicable for the development of a gonococcal vaccine. These
findings suggest that ongoing structure-function analyses will be critical, in order to determine
how to minimally alter protein residues to reduce binding while still maintaining a native overall
protein structure.
In order to further the study of TdTs and their potential use in a cocktail vaccine, we
developed a platform to characterize the structure function relationship of the Hb receptor
protein, HpuA. The rationale for this project is similar to the TbpA structure function project: to
characterize and exploit iron uptake mechanisms that allow for gonococcal survival during
exposure to host nutritional immunity. HpuA and HpuB are not as well studied as some of the
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other TdTs, so there are unanswered questions about how the gonococcus utilizes Hb as an iron
source. In addition, although the Hb receptor is phase variable, HpuA and HpuB may still be
helpful additions to a potential cocktail vaccine. Further structure-function analyses, based on
the recent report of the HpuA crystal structure (275), would aid the approach of trying to
develop non-ligand binding versions of the proteins, which may improve their immunogenicity.
It is also possible that expression of the Hb receptor could undergo a compensatory increase in
instances where other iron acquisition systems are impaired, as could be the case if the Tf
receptor is effectively inhibited by antibodies. Beyond gonococcal infection, studies of the
HpuAB system would have implications for other pathogens known to express the Hpus to use
Hb as an iron source during infection. Neisseria meningitidis, along with Kingella and Eikenella
species (members of the HACEK group of endocarditis causing organisms) also express HpuA
and HpuB for acquisition of Hb-iron in the blood (275). Although there are some differences in
sequence and loop structures among species, investigation of the HpuAB receptor of N.
gonorrhoeae is likely to yield information that will have meaningful overlap across species.
In order to impact gonococcal growth in the acute setting, we developed and tested novel
small molecules that could interrupt TbpA Tf-iron acquisition. Given that iron is an essential
nutrient, Tf is the primary source of iron in vivo, and that we now have the crystal structure of
TbpA (190) we hypothesized that these molecules could have antimicrobial effects on
gonococcal growth. The molecules were designed to mimic the structure of human Tf in specific
binding pockets of TbpA, with the hope that they could compete for TbpA binding. During
whole cell Tf binding assays, we have observed modest preliminary inhibition of TbpA-Tf
binding. In future studies, the compounds with modest effects could be structurally refined in
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attempts to increase TbpA-Tf binding inhibition. These assays constitute a novel approach to
antimicrobial development for the gonococcus. Because there are redundant iron acquisition
systems in the gonococcus, this model can and should be applied to multiple receptors systems
in order to maximize iron starvation.
In our last project, we departed from the TdTs to test a novel antimicrobial target, DnaK.
The novel chemotherapy agent OSU-03012, a derivative of celecoxib, had promising results in
initial cancer studies (287, 294). When it was determined that its mechanism of action was
inhibition of protein folding by Hsp70 family chaperones (293, 294), it was hypothesized that
this drug might have antimicrobial properties through inhibition of the homologous prokaryotic
protein, DnaK. We determined that OSU was bactericidal in gonococcal culture, even against
drug resistant gonococcal strains, at physiologically achievable doses. We were unable to
demonstrate synergy between OSU and PDE-5 inhibitors; however, OSU was synergistic with
cephalosporin and macrolide class antibiotics. Although the therapeutic window for OSU is
small, these data provide proof of principle that DnaK is a novel antimicrobial target. Further
studies are needed to determine if OSU-03012 can be structurally modified to improve its
pharmacodynamic properties. OSU’s activity extends beyond the gonococcus, as it has activity
against many other classes of bacteria, and also possesses antiviral properties (303). Additional
studies are needed to explore DnaK as a drug target, the spectrum of coverage that DnaK
inhibition would provide, and whether OSU specificity could be enhanced to affect prokaryotic
chaperones without affecting human proteins. Despite lingering questions, these preliminary
findings suggest DnaK may be a novel target for broad spectrum antimicrobial therapy, which
could have enormous impact on clinical practice.
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In sum, the data presented in this study has yielded new information for structure function
understanding of TdTs, for the development of a TdT based vaccine, and for novel gonococcal
drug targets. Understanding of the structure-function relationships in the TdTs will assist in
determining which domains are critical for protein function, and which residues could be
altered to optimize these proteins for vaccine development. The TdTs continue to stand out as
ideal targets for vaccine and drug development, as they are surface exposed, widely conserved
across gonococcal strains, and are not subject to high frequency phase or antigenic variation.
Additionally, these studies have provided new insights into a novel antimicrobial target, DnaK,
which is widely conserved across bacterial species. These findings have opened new avenues of
investigation to further develop protective and therapeutic treatment options for gonococcal
infection, which has and will continue to be a major public health concern.
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